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The emerging field of RNA nanotechnology has led to rapid advances in the applications 
of RNA in chemical biology, medicinal chemistry, and biotechnology. At the forefront of its 
utility is the ability to self-assemble multiple siRNAs into nanostructure formulations capable of 
targeting selected oncogenes and potentiating the gene therapy of malignant tumors. Self-
assembled siRNA integrates multiple siRNAs within a single molecular platform for silencing 
multiple oncogenic mRNA targets with high precision and efficacy to potentially induce cancer 
cell apoptosis through the RNA interference (RNAi) pathway. Furthermore, the conjugation of 
siRNA self-assemblies with bio-active probes results in multi-functional theranostic 
(therapy+diagnostic) agents capable of enhancing cancer cell detection and treatment. This 
includes the introduction of lipids for cell uptake, fluorophores for cell-based detection, and 
metallic nanoparticle formulations for optimizing siRNA biophysical and biological properties. 
The latter is a central focus of my thesis research objectives, aimed towards the development of 
self-assembled siRNA bioconjugates as effective anti-cancer agents.  
Glucose-regulated proteins (GRPs) are a class of chaperone proteins of the endoplasmic 
reticulum that serve as key sensors for misfolded proteins and trigger the unfolded protein 
response (UPR) under physiological and pathological stress conditions. Moreover, GRPs have 
been classified as clinically relevant biological markers in cancer detection and treatment and 
found to be over-expressed and cell surface localized in a wide range of cancer types. In cancer, 
the GRPs regulate cancer initiation, proliferation, adhesion, and invasion which contributes to 
metastatic spread and treatment resistance. Over the last decade, our research program has 





capable of silencing the oncogenic GRPs, and reversing their protective UPR effects related to 
proliferative, pro-survival, and anti-apoptotic pathways in selected tumors. Chemical tools have 
been implemented to improve the poor pharmacological properties of siRNAs to maximize their 
full therapeutic efficacy against tumorigenic disease conditions, which are highlighted in Chapter 
1 of this thesis.  
Chapter 2 highlights the development of synthetic strategies to improve siRNA metabolic 
stability, cellular uptake, and delivery, which are still in widespread demand for effective siRNA 
therapeutic applications. More specifically, this research aims to incorporate a small set of fatty 
acids into chemically derived siRNAs to improve their metabolic stability and cancer cell 
permeability. To achieve this goal, we have generated the higher-order siRNAs based on self-
assembled branching structures. The self-assembled branch siRNAs were generated from their 
corresponding RNA template strands, which incorporated a synthetic ribouridine branchpoint 
synthon. This monomer was developed by an efficient solution-phase synthesis route and can be 
effectively incorporated within linear, V, and Y-shaped RNA templates by automated solid-
phase RNA synthesis. Furthermore, an optimized coupling procedure has been developed for 
tagging variable saturated and unsaturated fatty acids onto linear, V- and Y-shape RNA 
templates. The RNA-fatty acid bioconjugates were analyzed, purified, and characterized by 
LC/MS. They were then hybridized with complementary RNA single strands to afford the 
amphiphilic self-assembled branch siRNA bioconjugates. The amphiphilic siRNA bioconjugates 
were detected by native PAGE, CD spectroscopy, and RP IP HPLC, while characterization of 
their self-assembled nanostructures was determined by DLS and TEM. Furthermore, the self-
transfection capabilities of the siRNA-fatty acid bioconjugates and their biological activities 





modest RNAi activity when compared to the siRNA controls transfected with a commercially 
available transfection reagent. Nonetheless, this reported solid-phase RNA bioconjugation 
approach provides an important entry point for the incorporation of various hydrophobic and 
amphiphilic functional groups. This strategy may enable further development of new generation 
RNAi molecules for screening important oncogene targets and for improving cancer gene 
therapy applications.  
Chapter 3 describes the synthesis, characterization, and biological evaluation of a new 
class of bifunctional gold (Au)-RNA nanoparticles to improve cellular uptake and theranostic 
utility of the multi-functional siRNA nanostructures in prostate cancer cells. In this study, we 
have developed a simple, bottom-up approach using alkylamino modified RNAs to produce 
stable and small Au-RNA nanoparticle formulations bearing either a fluorescent reporter 
(fluorescein) or a fatty acid group (palmitamide) to track cell uptake in PC-3 prostate cancer 
cells. The resulting Au-functionalized RNA particles were found to be stable under reducing 
conditions according to UV-Vis spectroscopy. Sample characterization by DLS and TEM 
confirmed self-assembly into primarily small (~10-40 nm) spherical shaped nanoparticles 
anticipated to be applicable to cell biology. The application of Au-functionalized siRNA 
particles in prostate cancer (PC-3) cells resulted in the knockdown of GRP75, which led to 
detectable levels of cell death in the absence of a transfection vector. Consequently, this novel 
Au-RNA theranostic formulation may prove to be a valuable bifunctional probe in the early 
detection and treatment of prostate cancer and related solid tumors.  
Chapter 4 of this thesis summarizes our on-going and future work aimed at incorporating 





treatment in cell cultures and within tumor-bearing mice models. The study aims to modify the 
Au-siRNA nanoparticle formulation with cell-targeting peptides (CTPs), which functions to 
target and bind to a cell surface receptor, in this case, PSMA, found on the surface of select 
prostate cancer cells. A PSMA-targeting peptide sequence has been selected for targeted delivery 
of the Au-siRNA formulation directly within PSMA+ prostate cancer cells for the application of 
cancer-targeting gene therapy. Taken together, this thesis will serve to highlight the synthetic 
strategies towards the development of higher-order self-assembled siRNA bioconjugates with 
self-transfection capabilities for silencing multiple oncogenic GRPs in cancer. 
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dsRNA  Double-Stranded Ribonucleic Acid 
DTT   Dithiothreitol 
e.g.   For example  
EDTA   Ethylenediaminetetraacetic Acid 
eGFP   Enhanced Green Fluorescent Protein 
EGFR   Epidermal Growth Factor Receptor 
EPR   Enhanced Permeability and Retention Factor 
ER   Endoplasmic Reticulum 
ESI-MS  Electrospray Ionization Mass Spectrometry 
ETT   5-ethylthiotetrazole 
F   Fluorine 
FA   Folate 
FACS   Fluorescence Assisted Cell Sorting 
FAK   Focal Adhesion Kinase  





FBS   Fetal Bovine Serum 
FITC   Fluorescein Isothiocyanate 
FL   Fluorescence 
FL-siRNA  Fluorescently Labeled siRNA 
FRET   Fluorescence resonance energy transfer 
G   Guanosine 
GalNAC  N-acetylgalactosamine 
GFP   Green Fluorescent Protein 
GAPDH  Glyceraldehyde-3-phosphate Dehydrogenase 
GRPs   Glucose Regulated Proteins 
GRP75  Glucose Regulated Protein, 75 kilodaltons 
GRP78  Glucose Regulated Protein, 78 kilodaltons 
GRP94  Glucose Regulated Protein, 94 kilodaltons 
H2O   Water 
HCTU O-(1H-6-Chlorobenzotriazole-1-yl),1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HCS   High Content Screening 
HER2   Human Epidermal Growth Factor receptor 2 
HeLa   Cervical Celllines 
HepG2   Hepatoblastoma Cell 
HPLC   High Performance Liquid Chromatography 
HSPA5  Heat Shock Protein Family A 
Hr   Hour 
HRP   Horseradish Peroxidase 
IGF-1   Insulin-Like Growth Factor 1 
KD   Knockdown 
KSP   Kinesin Spindle Protein 
LC/MS  Liquid Chromatography/ Mass Spectrometry 
LDH   Lactate Dehydrogenase 
LDS   Lithium Dodecyl sulfate 





Lv   Levulinyl 
M   Molar 
m/z   Mass to Charge Ratio 
Me   Methyl 
MeCN   Acetonitrile 
MEM   Minimum Essential Medium 
MeOH   Methanol 
mg   Milligram 
miRNA  Micro-RNA 
mA   Milliamp 
mL   Milliliter 
mM   Millimolar 
mmol   Millimole 
MMT   Monomethoxy Trityl 
mRNA   Messenger RNA 
MS   Mass Spectrometry 
n   nucleotide 
N   Nucleocapsid 
NAb   Neutralizing Antibody 
NaCl   Sodium Chloride 
NAION  non-arthritic anterior ischemic optic neuropathy 
n-BuOH  n-Butanol 
N-cad   N-cadherin 
ncRNA  Non-coding RNA 
ng   nanogram 
NIR   Near Infrared 
nm   Nanometer 
nM   Nanomolar 
nmol   nanomole 
NP   nanoparticle 





NMR   Nuclear Magnetic Resonance 
MDA-MB-231 Breast Cells 
PAGE   Polyacrylamide Gel Electrophoresis 
PBS   Phosphate-Buffered Saline 
PCa   Prostate Cancer 
PEI   Polyethyleneimine 
PI   Propidium Iodide 
PKN3   Protein Kinase N3 
PLGA   Poly Lactic-co-Glycolic Acid   
PLL   Poly-L-Lysine 
PLK   Polo-like Kinase 1 
pM   Picomolar 
pmol   Picomole 
PNA   Peptide nucleic acid 
PSMA   Prostate Specific Membrane Antigen 
PVDF   Polyvinylidene Fluoride 
qRT-PCR  Quantitative Real-Time Polymerase Chain Reaction 
RISC   RNA-Induced Silencing Complex 
RNA   Ribonucleic Acid 
RNAi   Ribonucleic Acid Interference 
RP IP HPLC  Reverse-Phase Ion Pairing High-Performance Liquid Chromatography 
RPMI   Roswell Park Memorial Institute Medium 
RRM2   Ribonucleotide reductase M2 subunit 
RSV   Respiratory syncytial virus 
rU   Ribouridine 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
saRNA  Small Activating RNA 
shRNA  Short-Hairpin RNA 
siRNA   Short-Interfering RNA 
ssRNA   Single Stranded RNA 





TAE   Tris/Acetic Acid/EDTA 
TBE   Tris/Borate/EDTA 
TBST   Tris-Buffered Saline/ Tween-20 
TEM   Transmission Electron Microscopy 
TES   Triethyl silane 
TF   Transferrin 
THF   Tetrahydrofuran 
TLC   Thin Layer Chromatography 
Tris   Tris(hydroxymethyl)aminomethane 
U   Uridine 
UNA   Unlocked nucleic acid 
UPR   Unfolded Protein Response 
UV-Vis  Ultraviolet- Visible Spectrophotometry 
VEGF   Vascular Endothelial Growth Factor 





Chapter 1: Theranostics Applications of siRNA and their Bioconjugates in 
RNAi Based Gene Therapy 
 
1.1 Discovery of the RNAi Mechanism  
The RNA interference (RNAi) mechanism of mRNA suppression remained enigmatic until 
the pioneering work of Victor Ambros’ group,1 and by American scientists Andrew Fire and 
Craig Mello.2 Their seminal work on the regulation of gene expression with the model 
organism Caenorhabditis elegans (C. elegans) led to the discovery of small, non-coding RNAs 
that interfered with gene expression at the mRNA level, leading to suppression of protein 
synthesis. Their efforts demonstrated that a simultaneous injection of sense and antisense double-
stranded RNA (dsRNA) targeting the mRNA transcript of the unc-22 gene exhibited very 
specific and operative inhibition of the uncoordinated (unc-22 & unc-54) genes. Inhibition of 
gene expression for the myofilament protein in C. elegans led to articulated twitching which 
suggested a direct correlation between gene suppression and functional responses within the 
organism. The proposed mechanism for gene suppression revealed the importance of the 
antisense RNA strand in targeting and suppressing mRNA expression resulting in the disruption 
of protein production and observable changes in phenotype characteristics. Subsequent to their 
findings, Guo and Kemphues3 worked on the inhibition of the par-1 gene in C. elegans, a major 
protein involved in the embryonic development of worms. This work led to the discovery of the 
effects of the sense RNA strand, which seemed to function by a separate mechanism compared to 
the antisense RNA strand and was found to be rather restricted as a putative passenger strand for 
a targeted mRNA region. Their mechanistic studies with nematodes revealed that upon treatment 
with sense and antisense dsRNA targeting the unc-22 gene, nematodes became strong twitchers. 




antisense single-stranded RNA (ssRNA), underscoring the critical importance of dsRNA-
mediated suppression of gene expression. The fundamental mechanism of RNAi was later 
confirmed by Fire and Mello.4 Based on their previous work on the suppression of unc-22 and 
unc-54 genes in C. elegans, complementary dsRNA sequences produced a more compelling loss 
in motor function when compared to the antisense or sense RNA sequences applied 
independently, even at lower dsRNA doses.4 Fire and Mellow were subsequently awarded the 
Nobel Prize in Physiology or Medicine in 2006 for their discovery of the RNAi pathway.5  
 
1.2 siRNA Structure and Function in RNAi Pathway 
Small interfering RNA (siRNA) is a class of non-coding RNAs composed of a 
complementary sense and antisense dsRNA containing 18-25 base-pairs.6-8 The dsRNA is 
composed of a well-defined structure consisting of a phosphorylated 5’-end and a hydroxylated 
3’-end typically containing a two nucleotide (nt) overhang. This small dsRNA also consists of an 
active guide (antisense) strand and an inactive passenger (sense) RNA strand. Considerable 
progress has been made to optimize the requisite parameters for stable dsRNA formation while 
designing siRNAs with enhanced RNAi potency. This includes optimization of thermodynamic 
properties by the implementation of algorithms used to create thermodynamically stable 
symmetric and asymmetric siRNAs. Computational analysis has been used to select the sequence 
compositions for the sense and antisense RNA strands that confers a stable A-type helix dsRNA 
secondary structure and binding specificity to targeted mRNA. Furthermore, siRNA 
modifications have been developed for enhancing RNAi activity while minimizing off-target 
silencing effects, and immunostimulatory activities that are known to cause toxicity. These 
modifications have also served to improve siRNA stability in biological media while enhancing 




and secondary structure motifs that may be implemented or modified for improved RNAi 
potency. A comprehensive study on a combinatorial library of chemically synthesized siRNA,9 
revealed four sets of rules based on optimizing the siRNA base composition of the sense strand. 
These include Rule 1: presence of A/U at position 19, GC at the first position, A/U at position 
10, 43 A/Us at position 13–19; Rule 2: presence of A/U at position 19, GC at the first position, 
GC at position 10, 43 A/Us at position 13–19; Rule 3: presence of G/C at position 19, GC at 
position 1, GC at position 11, 46 A/Us at position 5–19; and Rule 4: presence of A/U at position 
19, A/U at position 1, 43 A/Us at position 13–19. Taken together, these rules provide a general 
understanding of designing siRNAs of desired structure and sequence compositions for the 





Figure 1.1. Representative characteristics of siRNA sequence and structure compositions; green 
bases are in favorable positions, whereas bases in red should be avoided. Ago, Argonaute; CDS, 
coding sequence. Figure reproduced with permission from: Fakhr, E.; Zare, F.; Teimoori-






The RNAi pathway that occurs in plants, animals, and humans is a natural biological defense 
mechanism used for the inactivation of exogenous genes and theoretically can be applied to 
silence any disease-related genes in a sequence-specific manner.10 Thus RNAi modalities, 
siRNA, and microRNA (miRNA) provide therapeutic potential, by the knockdown of malignant 
gene expression in a sequence-specific manner by targeted mRNA translation inhibition and 
degradation (Figure 1.2).10-12 In this pathway, the active components of the RNAi machinery are 
identified and assembled to initiate the first step of the RNAi pathway. This involves the 
processing of long non-coding dsRNA or short hairpin RNA (shRNA) by binding to the 
cytoplasmic enzyme Dicer, a member of the RNase III family which subsequently cleaves the 
dsRNA into smaller siRNA fragments, typically 21-23 nucleotides in length.13 The siRNA is 
then recruited and bound onto the RNA-activated silencing complex (RISC) complex, which 
separates the antisense and sense RNA strands. The sense RNA strand dissociates from the RISC 
complex and eventually undergoes cleavage and degradation by endogenous nucleases, while the 
antisense RNA strand bound within RISC will target and bind to the corresponding mRNA 
sequence.14 The mRNA sequence undergoes inhibition of protein translation and degradation by 
the catalytic action of the Argonaute II ribonuclease subunit embedded within the active site of 
the RISC complex.15 In this manner, the RNAi mechanism is used ubiquitously for the regulation 
of gene expression in prokaryotes and mammalian cell types as well as in a wide range of 
organisms resulting in important adaptive and functional changes. It is also important in the 
defense against various invading pathogens or the elimination of gene expression within 
malignant cells. The latter holds therapeutic implications, as the design and development of 




range of human diseases.16 Thus, the RNAi pathway opens exciting possibilities for use in gene 






Figure 1.2. Schematic illustrations of the working mechanisms of miRNA (A) and siRNA (B). 
Figure reproduced with permission from: Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; 












1.3. Therapeutic siRNAs 
This RNAi method has already become an important research tool in biology and 
biomedicine. Significantly, after a long journey from its discovery, two clinical approvals of 
siRNA therapeutics, ONPATTRO® (Patisiran) and GIVLAARI™ (Givosiran) have been recently 
achieved by Alnylam Pharmaceuticals. These siRNA-based therapeutics are respectively used 
for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis; 
or for treatment of acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic 
porphyrin molecules which are formed during the production of heme.12 Furthermore, additional 
RNAi-based treatments are currently in the clinical pipeline for various diseases such as cancer, 
Huntington’s disease, chronic liver diseases, eye diseases such as glaucoma, and retinopathy in 
diabetes.17,18 
 
Among the other clinical siRNA candidates, QPI-1002 (I5NP) and QPI-1007 have been 
developed by Quark Pharmaceuticals targeting the p53 tumor suppressor for respectively treating 
acute kidney injury (phase 2 trials) and delayed graft function (phase 3 trials).19,20 Due to their 
biochemical nature, the QP-1002 siRNAs accumulated in the kidney at concentrations >40 times 
compared to other tissues and organs; and resulted in p53 mRNA eradication in proximal tubule 
cells at a concentration of ~1 nM. Furthermore, bilateral renal-clamp studies confirmed the 
preservation of kidney function following siRNA treatment. These therapeutic effects were also 
observed in siRNA-treated animals which showed ischemia with decreased serum creatinine 
levels from 3.7 mg/dL to 1.9 mg/dL with little toxicity observed at standard dosages. 
Comparatively, the QPI-1007 siRNAs targeted the pro-apoptotic mediator caspase-2, to treat 
acute primary angle-closure glaucoma (phase 2 trials) and non-arthritic anterior ischemic optic 




silencing in HeLa cells and reversed optic nerve damage in injured animal models without any 
serious side-effects.21 It was concluded that QPI-1007 significantly protected the optic nerve in 
pre-clinical and clinical trials, underscoring the therapeutic efficacy of siRNA treatment.22  
A clinical siRNA candidate, ALN-RSV01 (Asvasiran sodium), has also been developed to 
thwart the progression of infectious diseases. This unmodified siRNA targets the respiratory 
syncytial virus (RSV) nucleocapsid (N) gene which consequently inhibits viral replication.24 
Clinical data validated its beneficial effects on long-term allograft function in lung transplant 
patients infected with RSV,25-27 while another report showed that ALN-RSV01 aids in the 
prevention of bronchiolitis obliterans syndrome following lung syncytial virus infection in lung 
transplant patients.28 Similarly, other beneficial siRNAs have also been made to target various 
receptors such as polo-like kinase 1 (PLK1),29 kinesin spindle protein (KSP),30 and 
ribonucleotide reductase M2 subunit (RRM2);31 which play important roles in cell cycle 
progression; KRAS(G12D)32 implicated in cell signaling; protein kinase N3 (PKN3)33,34, 
tenascin C35, and for cell proliferation and angiogenesis vascular endothelial growth factor 
(VEGF)36,37 is involved. Thus, therapeutic siRNAs have been used to target a wide range of 
biological markers implicated in a variety of disease states ranging from infectious to metabolic 
and genetic disorders.   
1.4. Limitations of therapeutic siRNAs and remedial strategies  
However, the development of RNAi-based therapeutics is not without challenges.38,39 
Namely, the small RNA molecule may be effectively cleared via the renal system thereby 
restricting its therapeutic index. Native siRNAs are also widely susceptible to nuclease digestion, 




immunological response by binding and activating certain receptors of the innate immune 
system. For example, Toll-Like Receptors (2), have been activated by siRNAs, igniting a 
cytokine/chemokine storm which may have detrimental side-effects and widespread toxicity. 
Among their most significant limitations, siRNAs are negatively charged and lack cell 
permeability. Delivery of native siRNAs into cells has been a paramount challenge, generally 
resulting in poor transfection efficiency and ineffective gene therapy. To overcome this 
challenge, several methods have been implemented―electroporation, calcium phosphate 
transfection, and microinjection for effective siRNA delivery into target cells.40 However, these 
methods are complex and tedious. Moreover, they are not suitable for long-term gene silencing 
effects and in vivo applications.   
To overcome these challenges, a thorough evaluation of the sequence and structure 
compositions, biological potency, and toxicity parameters that may be optimized is critical for 
enhanced siRNA biological performance. Chemical modifications, self-assembly, and delivery 
formulations of siRNA have been developed to fulfill the functional requirements of siRNA 
activity while minimizing toxicity. Advancements in nucleic acid chemistry, bioconjugation 
approaches, programable and non-programmable self-assembly strategies related to RNA 
nanotechnology, delivery strategies with viral and non-viral vectors, and functionalized 
nanocarriers have all been applied for optimizing the efficiency of siRNA activity in target cells. 
The application of lipids, polymers, nucleic acids, proteins, and organic/inorganic materials have 
improved the biomedical applications of siRNAs in imaging,41,42 sensing,43 targeted drug 
delivery,44 electronics, and nanomedicines.45 Thus, siRNAs may be readily modified or 





1.5. Chemically modified siRNAs 
Chemically modified siRNAs (cm-siRNAs) have also been developed to improve the 
biophysical and biological properties of the native siRNAs. Typically, the most popular 
strategies include chemical modifications of the ribose sugar, modification of the phosphodiester 
backbone, and nucleobase changes which impacts hybrid stability (Figure 1.3).12,46 The ribose 
sugar chemical modifications include the substitution of the 2’-hydroxyl (2’-OH) group with 2’-
fluorine- (2’-F), 2’-O-methyl- (2’-O-Me), and 2’-amino- (2’-NH2) substitutions which are 
isosteric and isoelectronic compared to native RNA allowing for dsRNA hybrid formation. 
Bulkier modifications, including 2’-O-methoxyethyl (2’-O-MOE), have more significantly 
impacted RNA folding. Similarly, 2’-methylene bridged locked nucleic acids (LNA) and 
unlocked nucleic acids (UNA), have served to increase RNA chemical and thermal stability 
while maintaining RNAi activity relative to control siRNA.12,46-50 Furthermore, modification of 
the phosphodiester linkage has served to increase siRNA serum stability. The site-selective 
incorporation and/or replacement of the phosphodiester backbone with a phosphorothioate 
(substitution of the non-bridging oxygen for a sulfur atom);51 boranophosphate (substitution of 
the non-bridging oxygen for a borane)52 or an amide linkage (peptide nucleic acids, PNA).53 The 
latter modification replaces the negatively charged phosphate with the neutrally charged amide 
bond, which evades nuclease and protease digestion, thereby increasing the chemical stability 
and gene silencing activity of cm-siRNAs.54 Interestingly, these modifications have also 
minimized off-target gene silencing effects which have resulted in diminished toxicity. The 
single incorporation of 2’-O-Me and LNA within cm-siRNAs has been shown to improve the 
stability and specificity of the siRNA target gene silencing activity.55 Modifications to the 




Some of these modifications include 5-bromouracil and 5-iodouracil as uracil derivatives, 
diamino purine as an adenine analog, 2-thiouracil, 4-thiouracil, pseudo-uracil, 5-methylation of 
pyrimidines, nonaromatic bases, and dihydrouracil. In most cases, the chemical RNA stability is 
significantly enhanced, however, the base-pairing function can be altered depending on the 
location of the modified bases within the sequence. Therefore, nucleobase modifications are less 
common in cm-siRNA therapeutic applications, although they have contributed to the basic 
understanding of the molecular requirements for siRNA hybrid formation and thermodynamic 
stability.57 Taken together, chemical modifications have served to improve the stability, and 
biological activity of siRNAs while minimizing toxicity associated with off-target gene silencing 
or immunostimulatory activities. Thus, cm-siRNAs are preferred analogs that have served to 





Figure 1.3. Structures of cm-siRNA. These structures can be divided into three classes: 
phosphodiester backbone, a ribose sugar, and nucleobase modifications, which are marked in red, 
purple, and blue, respectively. R = H or OH, for RNA or DNA, respectively. (S)-cEt-BNA (S)-
constrained ethyl bicyclic nucleic acid, PMO phosphorodiamidate morpholino oligomer. Figure 
reproduced with permission from: Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; Zhao, Y.; 




1.6. siRNA Bioconjugation  
Structural and chemical modifications that facilitate the incorporation of functional 
chemical ligands, such as fluorescent dyes, lipids, chemotherapeutic drugs, or biotin, within 
RNA by well-established chemical conjugation strategies have served to improve the utility of 
siRNA bioconjugates (Figure 1.4).58 For example, siRNA bioconjugates have been synthesized 
by Click chemistry, using the copper-catalyzed azide-alkyne cycloaddition (CuAAC).59 This 
conjugation approach produced a series of lipidated siRNA derivatives functionalized with long-
chain alkyl, cholesterol, oligoamine, and carbohydrate groups. The siRNA bioconjugates resulted 
in luciferase knockdown within HeLa cells, thereby validating their potential utility in cancer 
gene therapy applications. A cancer-targeting approach was realized with folic acid PEG-
conjugated siRNAs, prepared by the Cu(I) catalyzed 1,3-dipolar cycloaddition reaction. The 
functionalized siRNA displayed selective cell line permeability, in Neuro2A cells overexpressing 
the folate receptor on the cell surface. Cell uptake triggered silencing of the reporter Green 
Fluorescent Protein (GFP) thereby validating its applicability in receptor-guided gene 
silencing.60 It has been shown that targeting ligands may enable binding affinity and cellular 
uptake via receptor-mediated endocytosis leading to improved RNAi efficacy of the siRNA 
bioconjugates relative to their native counterparts. For example, the anisamide conjugated 
siRNA combined with a hepta-guanidino -cyclodextrin-PEG (G-CD-PEG) copolymer produced 
a multifunctional formulation which was found to stabilize the nanoparticles in physiological 
media and extended their circulation time in vitro. These desirable pharmacokinetic effects 
enabled selective binding affinity and effective cell uptake via the targeted s-receptor on the 
surface of PC-3 human prostate cancer cells, resulting in silencing of the reporter luciferase 




chemistry has significantly improved delivery to hepatocytes in vitro and in vivo by binding to 
the asialoglycoprotein receptor (ASGPR), followed by receptor-mediated cellular 
internalization.62,63 It has been shown that multivalent GalNAc clusters conjugated to siRNAs 
resulted in potent RNAi-mediated gene knockdown in hepatocytes at therapeutically relevant 
doses in mice validating their potential to treat liver-associated genetic disorders. Cell-targeting 
peptides (CTPs) have also been used as homing agents for specific cellular and tissue delivery of 
siRNA bioconjugates. In a selected application, cRGD peptides targeting the integrin receptors 
were conjugated to siRNA following Michael addition chemistry of the thiolate functionalized 
siRNA with the maleimide containing cRGD peptides.64 The cRGD-siRNAs targeting the 
luciferase reporter gene in αvβ3 positive M21+ human melanoma cells produced progressive, 
dose-dependent knockdown, illustrating the synergistic effects of the multi-valent cRGD 
presentation of the cRGD-siRNA bioconjugates.65 Selective conjugation approaches have also 
been developed in between monoclonal antibodies (mAbs) and siRNAs to improve therapeutic 
efficacy. For example, the Human Epidermal Growth Factor Receptor 2 monoclonal antibody 
(anti-HER2 mAb) bearing an aminooxy-functionalized cationic block copolymer facilitated 
condensation of GAPDH-silencing siRNA for delivery within HER2+ tumors.66 Following 
treatment, GAPDH levels were significantly reduced underscoring the therapeutic potential of 
targeted gene delivery approaches. Of relevance to the complementary work reported in this 
thesis, gold (Au) nanoparticles have been used to track siRNA activity in cells. Bioconjugation 
of poly-lysine to Au-nanoparticles enabled condensation and controlled release of siRNA 
silencing the GFP reporter in H1299 cells following exposure to near-infrared light.67 Thus, 






Figure 1.4. Representative examples of siRNA-based bioconjugates. Figure adapted with 
permission from: Patel PL, Rana NK, Patel MR, Kozuch SD, Sabatino D. ChemMedChem. 2016, 
1(3), 252-269.58  
 
 
1.7. Self-Assembled siRNA Nanotechnology 
Advances in RNA structural biology have improved our understanding of the structures 
and folding properties of naturally occurring self-assembled RNAs.68 The architectural potential 
of RNA relies on the ability of a single RNA strand to fold into thermodynamically stable three-
dimensional structures. The incorporation of functional and structural RNA elements has been 
used to template the construction of high-order RNA structures. The presence of secondary 
structure RNA motifs― bends, stacks, junctions, loops, and chelates with divalent metal cations 




buffered pH have improved RNA structural stability and functional utility.69 Several types of 
functional RNA or RNA elements have been applied in RNA self-assembly and nanotechnology 
including the formulation of siRNA nanostructures for multifunctional and synergistic RNAi 
activities.70-80  
Some relevant examples of siRNA nanostructures (Figure 1.5) include the dumbbell-
shaped nanocircular RNAs which triggered Dicer enzyme cleaving activity resulting in the 
formation of bio-active siRNAs for RNAi activity.81-83 Trimer or tetramer RNA, containing 
multiple siRNA motifs embedded within the same higher-order molecular structure resulted in 
the intracellular release of siRNA for prolonged gene silencing activity as the siRNA 
nanostructures were found to be stable towards nuclease digestion.84,85 The nano ring-shaped 
tectoRNAs also provided unique self-assembled molecular nanostructures which facilitated 
efficient siRNA cellular delivery for RNAi activity.86 A spherical RNA nanostructure identified 
as the siRNA nano-sheet was synthesized by rolling circle transcription, effectively processed by 
Dicer resulting in siRNA production for the inhibition of mRNA expression.87 The 
complementary RNA nanocubes formed an interesting class of nanostructures incorporating six 
dsRNA Dicer substrates, when cleaved produced six siRNAs which resulted in the suppression 
of the reporter, enhanced green fluorescent protein (eGFP) for up to twelve days in breast cancer 
cells using Lipofectamine as a transfection reagent.78 In a related study, RNA nanorings 
containing multiple siRNAs within the nanoparticle formulation resulted in eGFP knockdown.88 
In a recent application, a synthetic supramolecular RNA nano-architecture was used to template 
the design of a novel truncated tetrahedral siRNA scaffold.89 The modular pieces of 
complementary RNA self-assembled into a tetrahedral siRNA scaffold with enhanced cellular 




aptamers for selective binding to the epidermal growth factor receptor overexpressed on human 
breast cancer cells. Cell uptake of the RNA nanoparticles led to persistent eGFP knockdown. 
Branched siRNA nanostructures self-assembled into three- and four-way junctions have also 
been designed and developed for targeting the luciferase reporter gene for up to five days in 
HeLa cells.90 Thus, the ability for higher-ordered siRNA nanostructures to behave as Dicer 
substrates, resulting in the release of multiple siRNAs that ultimately results in potent gene 
knockdown effects underscores the potential utility of siRNA nanostructures in RNAi screening 
and gene therapy applications. 
In our contributions to RNA nanotechnology, we have developed a novel synthetic method 
for the generation of linear, V, and Y-shape RNA templates that can self-assemble into high-
order siRNA nanostructures.91,80  In this work, higher-order branch and hyper branch siRNAs 
were synthesized by solid-phase RNA synthesis incorporating an orthogonally protected RNA 
branchpoint nucleotide which enabled selective construction of the branch RNA templates.91 The 
branch RNA templates were designed with sequence composition targeting the Glucose 
Regulated Protein of 78 kilodaltons (GRP78) which has been classified as a clinically relevant 
biological marker in the treatment of cancer. The branch siRNAs were found to be stable in 
annealing buffer and Lipofectamine-based transfections in HepG2 liver cancer cells resulted in 
suppression of GRP78 expression and to a more significant extent compared to treatment with 
the control, linear siRNA. Our efforts to expand the repertoire of functional siRNA 
nanostructures culminated with the application of the previously described linear, V-shape, and 
Y-branch RNA templates to self-assemble with complementary RNA to form a variety of siRNA 
nanostructures.80 The siRNA nanostructures were genetically encoded to target multiple GRPs 




The siRNA nanostructures revealed the influence of GRP activity on cancer cell viability, 
whereby GRP silencing with the multi-GRP targeting siRNA nanostructures resulted in the most 
potent anti-cancer effects. Interestingly, GRP silencing in a non-tumorigenic lung cell line 
displayed modest toxicity effects, underscoring the importance of GRP overexpression and 












Figure 1.5. Representative examples of siRNA nanostructures. Figure adapted with permission 
from Refs. 78, 81, 85, 87-89 (Afonin, K.A.; Viard, M.; Kagiampakis, I.; Case, C.L.; 
Dobrovolskaia, M.A.; Hofmann, J.; Vrzak, A.; Kireeva, M.; Kasprzak, W.K.; Kewal Ramani, 
V.N.; Shapiro, B.A. Triggering of RNA Interference with RNA–RNA, RNA–DNA, and DNA–
RNA Nanoparticles. ACS Nano. 2015, 9(1), 251-259); (Abe, N.; Abe, H.; Ito, Y. Dumbbell-
shaped nanocircular RNAs for RNA interference J. Am. Chem. Soc. 2007, 129,(49) 15108-
15109); (Nakashima, Y.; Abe, H.; Abe, N.; Aikawa, K.; Ito, Y. Branched RNA nanostructures 
for RNA interference. Chem. Commun. (Camb), 2011, 47(29), 8367-8369); (Kim H, Lee JS, Lee 
JB. Generation of siRNA Nanosheets for Efficient RNA Interference. Sci Rep. 2016; 6, 25146) 
;(Afonin, K.A.; Viard, M.; Koyfman, A.Y.; Martins, A.N.; Kasprzak, W.K.; Panigaj, M.; Desai, 
R.; Santhanam, A.; Grabow, W.W.; Jaeger,  L.; Heldman, E.; Reiser, J.; Chiu, W.; Freed, E.O.; 
Shapiro, B.A. Multifunctional RNA Nanoparticles. Nano Lett. 2014, 14, 5662-5671); 
(Zakrevsky, P.; Kasprzak, W.K.; Heinz, W.F.; Wu, W.; Khant, H.; Bindewald, E.; Dorjsuren, N.; 
Fields, E.A.; de Val, N.; Jaeger, L.; Shapiro, B.A. Truncated tetrahedral RNA nanostructures 




  Although we have developed a versatile strategy for the rapid construction of higher-order 
siRNA nanostructures, the inherent challenges associated with cellular RNA delivery and 
stability continue to limit its in vitro and in vivo efficacy, thereby increasing the demand for 
more effective RNA delivery carriers and transfection methods.  
  
1.8 siRNA Delivery Systems 
 
The rapidly emerging applications of gene therapy and therapeutic nucleic acids for the 
replacement or silencing of target malignant genes have increased the demand for the 
development of effective delivery strategies. Several biological barriers restrict the delivery and 
release of siRNAs into target cells for efficient RNAi activity (Figure 1.6). Among the various 
extra- and intra-cellular barriers dampening siRNA efficacy are the endothelial and epithelial 
barriers, as well as tight junctions in selective tissues (e.g., the blood-brain barrier) that limits 
siRNA permeability. Furthermore, changes in pH, enzymatic digestion, and scavenging by the 
immune system may significantly impact siRNA biodistribution and therapeutic index. These 
barriers affect siRNA cellular targeting and penetration, intracellular trafficking, endosomal 
escape, and RNAi activity which ultimately leads to diminished therapeutic activity in the 
absence of an effective delivery system.92,93 Therefore, it is difficult to achieve the desired 
therapeutic effect by direct, fusogenic siRNA delivery due to several biological and cellular 










Figure 1.6. Biological barriers (A) Extracellular barriers to RNAi therapy. (a) Endonucleases 
degrade siRNA in circulation; (b) mononuclear phagocytic system, in particular, the 
macrophages remove siRNA within the major clearance organs (such as liver, lungs, and spleen); 
(c) tissue penetration of siRNA is hindered by charge repulsion between the anionic siRNA and 
the plasma membrane of endothelial/epithelial cells, as well as tight junctions in selective regions 
(e.g., the blood-brain barrier) that require transcellular or paracellular transport to reach the target 
tissue. (B) Intracellular barriers to RNAi therapy: endocytosis versus fusogenic uptake. (a) 
Endocytosis of siRNA, which eventually is excreted via vesicle trafficking and exocytosis, leads 
to negligible efficacy. (b) Endocytosis of siRNA, which carries the siRNA through early to late-
stage endosomes, and lysosomes for acidification and degradation, also gives minimal efficacy. 
(c) siRNA can escape from the early endosomes to undergo RNA interference (RNAi) within the 
cytoplasm, but at attenuated potency due to inefficiency of the escape mechanism. (d) Fusogenic 
uptake of siRNA that leads to immediate cytosolic localization and RNAi. Figure adapted with 
permission from: Subhan, M.A.; Torchilin, V.P. siRNA-based drug design, quality, delivery, and 




The intracellular delivery of siRNAs is a challenging task requiring optimization of 
biological or synthetic vectors which can facilitate efficient cell uptake for RNAi activity.93 Cell 




internalization, iii) escape from endocytic vesicles, iv) transport through the cytoplasm and 
release of siRNA to complex with RISC and activate the RNAi pathway for silencing mRNA 
expression (Figure 1.7).94 The selection of effective delivery vehicles that may facilitate siRNA 
bio-activity require A) selection of a proper administration route, e.g. oral vs intravenous or 
infusion injections; B) a colloidal delivery system capable of efficiently condensing siRNA into 
small, monodispersed nanoparticles (≤ 80nm) to penetrate the biological barriers; C) cell-
penetration and release of the siRNA into the cytoplasm for RNAi activity; which may produce a 





















Figure 1.7. Schematic representation of siRNA nanoparticle delivery, uptake, and release into 
the cytoplasm for RNAi activity. siRNA nanoparticles may be encapsulated or complexed with a 
suitable delivery agent for cell uptake. Following cell uptake by endocytosis, siRNA triggers 
endosomal escape and recruitment of the RNAi components, Dicer enzyme (purple) processes 
siRNA substrates for RISC (blue) which recruits mRNA leading to inhibition of protein 
translation and mRNA degradation.  Figure reproduced with permission from: Parlea, L.; Puri, 
A.; Kasprzak, W.; Bindewald, E.; Zakrevsky, P.; Satterwhite, E.; Joseph, K.; Afonin, K.A.; 














Figure 1.8. Representative siRNA delivery systems for RNAi drug development. Canonical 
liposome formulations (a), DPCiv™ (b), RONDEL™ (c), LODER polymer (PLGA matrix) (d), 
EnCore liposome (e), EDV™ nano cell (f), peptide nanoparticle (g), exosome (h), GalNAc-oligo 
conjugate (i), Multi-RNAi-microsponge (j), pRNA-3WJ (k) and fluorinated oligoethylenimine 
nano assembly (l) Figure reproduced with permission from: Weng, Y.; Xiao, H.; Zhang, J.; 
Liang, X.J.; Huang, Y. Biotechnology Adv. 2019; 37, 801-825.95 
 
 
Multiple delivery systems based on viral and non-viral vectors have been developed to 
introduce siRNA safely and effectively within their cell targets (Figure 1.8).95 Successful 




associated, and poxvirus vectors, among others. However, viral vectors are limited by significant 
immunogenicity, toxicity, and transgenic capacity size restrictions for efficient cell uptake.96,97 
Nonviral vectors are based on physical and chemical systems, which generally include chemical 
modifiers introduced by bioconjugation strategies that may facility siRNA delivery (e.g. lipid or 
GalNac functionalization) or self-assembly techniques involving: cationic liposomes, polymers, 
peptides, antibodies, and nanomaterials.98,99 Physical methods have also been developed for 
direct transfection of siRNA into target cells. These strategies include particle bombardment, 
magnetofection, and ultrasound electroporation100 or hydrodynamic injection,101 applications. 
However, these physical methods have failed in commercial gene therapy due to their tendencies 
to drastically affect/alter cell-based compositions.102 Therefore, nonviral vectors have gained the 
most traction in recent years due to favorable pharmacological properties while providing 
efficient and safe siRNA delivery. These synthetic delivery systems include: nanoparticles 
(NPs), liposomes, dendrimers, and cationic polymers due to their efficient siRNA 
condensation/release profiles in vitro and in vivo.103 Liposomes and lipid-like materials, based on 
unilamellar, multilamellar, solid-lipid nanomaterials, and lipidoids have been commonly used for 
nucleic acid delivery vehicles. The cationic lipid DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N, N, 
N trimethyl ammonium chloride) has been applied in siRNA transfections into the mouse, rat, 
and human cell lines.104 Despite their utility, liposomes possess safety and toxicity concerns due 
to off-target gene silencing effects as these types of formulations are dispersed in most cell types 
and immunostimulatory side-effects have been reported in vitro and in vivo.104 Modified 
liposomes have been engineered to address these limitations. Application of PEGylated 
liposomes bearing dialkyl and trialkyl cationic lipids were used for generating siRNA lipoplexes 




marked decrease in gene silencing effects relative to control conditions.105 To address this 
limitation, cell targeting/penetrating reagents, have been added to functionalized lipid-siRNA 
formulations. For example, a breast cancer binding peptide has been conjugated to the 
PEGylated liposome for efficient siRNA delivery within MCF-7 breast cancer cells.106 The 
targeting peptide ligand, DMPGTVLP, displayed selective binding and cell uptake within MCF-
7 cells resulting in significant down-regulation of PRDM14 gene expression and PRDM14 
protein synthesis, underscoring its potential utility in cancer-targeted gene therapy. Similarly, 
cell-targeting cationic polymers, such as polyethyleneimine (PEI) have been used as suitable 
siRNA delivery agents due to their ability to condense siRNA and facilitate endocytosis and 
endosomal escape due to the ‘proton-sponge’ effect.107 In this release mechanism, the ionic PEI-
siRNA cargo within the endosome leads to an accumulation of ions and an osmotic pressure 
effect that eventually bursts the endosome and releases the siRNA for RNAi activity.108 In a 
clinically relevant application, co-delivery of the potent chemotherapeutic, doxorubicin, and 
siRNA targeting VEGF expression was formulated within a cholic acid conjugated PEI 
copolymer containing folic acid as targeting ligand for direct delivery in nude mice bearing 
human colorectal adenocarcinoma.109,110 Tumor regression as a result of the combined 
chemotherapeutic and gene therapy effects were observed and specifically related to higher 
levels of apoptosis and necrosis detected from the histological analysis. In this manner, various 
targeting ligands such as small molecules (e.g. folate) peptides and proteins (e.g. transferrin, cell-
targeting peptides) and biologics (e.g. monoclonal and polyclonal antibodies) have been 
formulated with siRNA-delivery agents for more effective and selective gene delivery.111-115 As a 
representative example, a multi-component delivery system has recently been described and 




peptides) and several lipids (DOTAP, DOPE, cholesterol, and phosphatidylcholine) to form a 
nanoparticle which enabled siRNA encapsulation and release profile and cellular uptake for 
RNAi activity.115 The formulation effectively silenced Src and RPS6KA5 in the triple-negative 
human breast cancer cell line MDA-MB-231, compared to naïve cells, underscoring their 
potential utility in cancer gene therapy. Compared to their organic/synthetic counterparts, 
inorganic nanoparticles have also been applied in siRNA-mediated transfections and offer a wide 
range of beneficial properties. For example, the high luminescence of quantum dots (QDs),116 
superparamagnetic behavior of iron oxide nanoparticles117, and localized surface plasmon 
resonance of gold nanorods,118 have enabled theranostic (therapy+diagnostic) utility in siRNA 
delivery applications. For example, poly(acrylic acid) and quantum dot excipients were 
combined with a PEGylated cationic polymer for the condensation and release of therapeutic 
siRNA.119 Significantly, the quantum dots enabled stable polyplex formation which was 
visualized by cryogenic transmission electron microscopy (cryo-TEM) and promoted selective 
siRNA release upon polyplex disassembly according to Förster resonance energy transfer 
(FRET). The application of multifunctional and responsive materials in siRNA delivery has thus 
significantly increased their therapeutic utility.  
 
1.9 Thesis Objectives  
The research work described in this thesis is based on selected types of synthetic RNA 
motifs including linear, V, and Y-shaped RNA templates with the ability to self-assemble into 
higher-order siRNA nanostructures.80,91 These multi-functional siRNAs enabled the knockdown 
of the Glucose Regulated Proteins (GRPs) in selected tumor cell lines to explore the influence of 
these chaperone proteins on tumor viability. This RNAi screening approach provides an 




siRNA therapeutic activity by the synergistic action of silencing multiple oncogenes 
concurrently. Our synthetic RNA work has also enabled the bioconjugation or assembly of cell-
penetrating and cell-targeting peptides,120 lipids,121 fluorescent probes122, and inorganic 
nanoparticles123 for enhancing siRNA delivery and detection while maintaining potent 
knockdown of oncogenic GRP targets for gene therapy in cancer cells.124,125 The novel synthetic 
biology approaches described in this thesis advances these preliminary studies, and serves to 
effectively improve the utility of siRNA-based biomaterial formulations for successful RNAi 
applications in the detection and treatment of cancer. 
Chapter 2 of this thesis describes a novel synthetic strategy for the incorporation of a 
small set of fatty acids into chemically derived siRNAs to improve their metabolic stability and 
cancer cell permeability for RNAi activity. The linear, V- and Y-shape RNA templates (sense 
and antisense strands), were functionalized with a hexylamino linker which was also used as a 
nucleophile in the solid-phase bioconjugation of saturated and unsaturated fatty acids with RNA 
templates (Figure 1.9). The RNA-fatty acid bioconjugates were successfully synthesized 
following an optimized HCTU coupling procedure, purified, and hybridized with complementary 
RNA single strands to afford the amphiphilic self-assembled branch siRNA bioconjugates. The 
bioconjugates were characterized by RP HPLC, MS, DLS, and TEM to confirm the structural 
and biophysical properties. Furthermore, the self-transfection of the siRNA-fatty acid 
bioconjugates and their biological activities within a model PC-3 prostate cancer cell line 
revealed partial cell uptake, which contributed to modest RNAi activity when compared to the 
siRNA controls delivered with the commercially available Lipofectamine transfection reagent. 
Nonetheless, this solid-phase RNA bioconjugation approach provides an important entry point 




development of new RNAi molecules for screening important oncogene targets and for 
improving cancer gene therapy applications.  
 
 
Figure 1.9 Graphical representation of linear, V-, and Y-shape siRNA templates covalent 
bioconjugation strategy for the introduction of fatty acid or fluorescent probes. Figure 
reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, 




Chapter 3 describes a simple, bottom-up approach for templating RNAs onto gold (Au) 
surfaces for the generation of produce stable Au-siRNA nanoparticles. Further functionalization 
of the RNA strands using our bioconjugation approaches facilitated the incorporation of a 
fluorescent reporter (FITC) or a fatty acid (palmitic acid) used to track cell uptake in PC-3 




found to be stable under reducing conditions, and self-assembled into primarily small (~10-40 
nm) spherical shaped nanoparticles. The incorporation of FITC within the Au-RNA 
nanoparticles produced a bifunctional probe, which facilitated cell uptake detection in a time-
dependent manner. The dual encapsulation-release profiles of the FITC-labeled Au-RNA 
nanoparticles were validated by time-dependent UV-Vis spectroscopy and spectrofluorimetry 
which showed increases in FITC absorption (λabs: 494 nm) and fluorescence emission (λem: 522 
nm) with increased sample incubation times, under physiological conditions. Cell biology 
revealed the release of siRNA functionalized Au nanoparticles in prostate cancer (PC-3) cells 
which resulted in concomitant knockdown of GRP75, and detectable levels of cell death. The 
direct transfection of multi-functional Au-siRNA nanoparticles may thus have important utility 












Figure 1.10. Graphical representation of the rational design of A) RNA sequence and B) 
bifunctional Au templated RNA particles. Figure reproduced with permission from: Shah, S.S.; 




In conclusion, Chapter 4 of this thesis will provide a general overview of current and on-
going work aimed at the production of the Au-siRNA nanoparticle formulation bearing cell-
targeting peptides (CTPs), for effective targeting and cell uptake in PSMA+ prostate cancer cells 
(Figure 1.11).  
 
Figure 1.11. Graphical representation of PSMA-specific bifunctional Au templated RNA 
particles with varying cell-targeting peptides. Figure Drawn using Chemdraw Professional 
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Chapter 2: Direct Transfection of Fatty Acid Conjugated siRNAs and 




RNA interference has led to rapid advances in the therapeutic applications of siRNAs 
including recent clinical candidates that have been approved for treatment of rare hereditary 
diseases. In this thesis chapter’s contribution towards the development of therapeutic siRNAs, an 
efficient bioconjugation approach has been developed for the ligation of linear, V and Y-shaped 
RNA templates with a small set of saturated and unsaturated fatty acids. This bioconjugation 
approach is hypothesized to improve siRNA cell uptake and knockdown efficacy of the glucose 
regulated proteins (GRPs) in prostate cancer cells. An optimized HCTU-coupling procedure was 
developed and used for the amidation of saturated and unsaturated fatty acids onto the 5’-ends of 
linear and V-shape RNA templates functionalized with an alkylamino linker that enabled solid-
phase conjugation. Reverse phase ion pairing HPLC was used to validate product conversions, 
while providing trends in amphiphilic properties. Hybridization and self-assembly of 
complementary linear RNA strands yielded linear, V- and Y-shape fatty acid-conjugated siRNAs 
which were characterized by native PAGE, CD spectroscopy, DLS and TEM which confirmed 
multi-component self-assembled structures that were prone towards aggregation. The fatty acid 
conjugated siRNA bioconjugates were evaluated for RNAi activity within GRP overexpressing 
prostate cancer (PC-3). The siRNA bioconjugates with sense strand fatty acid conjugation 
provided more potent GRP knockdown when compared to the antisense strand modified siRNAs. 
However, less GRP knockdown efficacy was observed when compared to the unconjugated 




revealed limited cell uptake of the fatty acid conjugated siRNAs which likely contributed to 
decreased RNAi activity of the fatty acid conjugated siRNAs without additional transfection 
vector delivery. Regardless, these constructs represent a new contribution higher-order siRNA 
modification that may lead to more efficient siRNA bioconjugates for cancer gene therapy 
applications. 
2.2 Introduction 
In the gene therapy of cancer, therapeutic siRNAs have been used for screening oncogene 
markers and gene therapy applications of malignant oncogenes.1,2 Their therapeutic effects by 
silencing oncogenes that are critically important for tumor survival, proliferation and invasion 
offers renewed hope in the clinical treatment of resilient tumors.3,4 However, the clinical utility of 
siRNAs remains off-set by a wide range of limitations, including poor metabolic stability, limited 
cell uptake, reduced therapeutic efficacy at the localized tumor site and off-target gene silencing 
effects, which limits their utility and increases side-effects.5 In order to address these limitations, 
chemical modifications or conjugation of siRNAs with biologically active functional groups or 
molecular probes have been applied in the diagnosis and therapy (theranostics) of maligant 
oncogene targets in cancer.6 
The Glucose Regulated Proteins (GRPs) are a family of chaperone proteins expressed in all 
cell types where they function in the unfolded protein response associated with protein folding 
under physiological or pathological stress conditions in the lumen of the endoplasmic reticulum.7 
In cancer, GRPs are overexpressed and may be trafficked to the cell surface where they confer 
tumor proliferation, metastatic spread and resistance towards drug treatment.8 The GRPs have thus 




therapeutic strategies have been developed to inhibit or silence the GRPs in cancer,9-11 however, 
off-target side-effects, immunogenicity, poor cell uptake and serum stability have limited their 
therapeutic efficacy raising the need for new and improved leads. Towards this goal, our group has 
previously established a synthesis method for linear, V-, Y- and hyper-branch shaped siRNAs. The 
siRNAs were designed with sequence compositions that target a single and multiple mRNA 
expression sites related to GRP78 expression.12 The GRP78-silencing siRNAs triggered notable 
GRP78 knockdown (50-60%) but only limited (10-20%) cell death in a pediatric liver 
hepatoblastoma cell line (HepG2). In order to improve the therapeutic activity of the siRNAs, the 
higher-order siRNA nanostructures targeting GRP-75, 78 and 94, led to a more potent knockdown 
(50-95%) followed by more significant increases in cell death (50-60%) across a wider panel of 
tumor types.13 Thus, a multi-GRP silencing approach has been proven to be an effective anti-
cancer strategy in both hematological and solid tumor types. In spite of these promising results, 
synthetic strategies that can help improve siRNA metabolic stability, cell uptake, and targeted 
delivery, are still in widespread demand and a focal point of the study described in this thesis 
chapter.  
siRNA bioconjugates have shown the potential to improve pharmalogical properties in 
preclinical and clinical studies related to cancer treatment.5,6,14-18 The incorporation of lipids (fatty 
acids, terpenes and steroids) are among the most widespread siRNA modifications that have 
improved metabolic stability, enhanced cell permeability and effected longer duration of action 
when compared to the control, non-labeled siRNA treatment conditions.19-28 Combinatorial 
libraries of lipid-functionalized (lipidoid) siRNAs have also been found to be effective within in 
vivo models, including the observation of potent, specific and durable gene silencing effects in 




liver, lung and peritoneal macrophages underscoring the potential clinical utility of lipidoid 
siRNA. However, these examples are typically limited in scope and the efficiency of lipid-siRNA 
functionalization as well as the location of incorporation, which is typically restricted to either 3’ 
or 5’ conjugation.30-34 Thus, new synthetic approaches that may effectively serve to increase the 
scope and functionality of modified lipid-siRNA bioconjgates may lead to the discovery of more 
potent RNAi therapeutics in the treatment of cancer and other morbidities. 
Despite their utility, lipid siRNA bioconjugates remain limited by their safe and effective 
delivery for potent and long-lasting suppression of malignant gene expression. In this study, we 
have built upon our previous work and that described by others in the literature19-34 by expanding 
the scope of lipidated siRNAs while attempting to address some of their limitations in RNAi 
applications. More specifically, the GRP-targeting linear, V- and Y-shape RNA templates were 
used for the incorporation of fatty acids to investigate their effects on the direct transfection, cell 
uptake and GRP knockdown in prostate cancer (PC-3) cells.  
2.3 Chapter Objectives 
   This thesis chapter describes the design, synthesis, characterization, and biological evaluation 
of lipidated siRNA nanostructures within human cancer cells. The work described within this 
chapter forms part of our on-going efforts in developing effective anti-cancer approaches via 
collaborative, multidisciplinary research. Based on our previous work on the branching RNA 
chemistry, we have expanded the scope of synthetic siRNA constructs with the development of 
high-order lipidated siRNAs while attempting to address some of the shortcomings of siRNAs in 
RNAi applications. The project objectives begin with the selection of the GRP-targeting linear, 




afford the GRP-silencing siRNAs. These siRNA sequences have been selected to target two sites 
of oncogenic GRP78 and those related to the GRP-75 and 94 mRNA sequences. The 
incorporation of a small library of fatty acids (saturated, unsaturated and polyunsaturated) at the 
5’ ends of the antisense and sense strands of linear, V- and Y-shape RNA templates provides 
lipidated RNA with variable structural and amphiphilic properties. These trends will be 
investigated by a combination of reverse-phase ion-pairing HPLC and UV-Vis 
spectrophotometry. Moreover, experimental studies conducted in collaboration with Drs. Jorge 
Ramos and Uri Samuni at Queen’s College, CUNY, will be based on dynamic light scattering 
(DLS) and transmission electron microscopy (TEM) which will provide valuable insights into 
the sizes, shapes, charge distribution and aggregation potential of the lipid-RNA particles. 
Furthermore, annealing with complementary RNA strands will facilitate the formation of 
lipidated siRNA with and without a fluorochrome (fluorescein isothiocyanate, FITC) label for 
investigating the influence of these functional probes on siRNA secondary structure (CD 
spectroscopy) and stability (thermal denaturation, native polyacrylamide gel electrophoresis and 
serum digestion) which is anticipated to have a direct impact on biological activity. The lipidated 
siRNAs will then be investigated in direct transfection and cell uptake studies (fluorescence 
microscopy and flow cytometry) as well as GRP knockdown at the mRNA (real time polymerase 
chain reaction, qRT-PCR) and protein (western blot) levels of expression within a metastatic 
prostate cancer (PC-3) cell line to determine their utility in cancer gene therapy applications. 
These biological assays will be conducted in collaboration with Drs. Christopher Cultrara and 
Jenny Zilberberg located at the Center for Discovery and Innovation at Hackensack-Meridian 
Health. The results and data presented in this chapter are published and adapted with permission 




J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Bioconjugate Chem., 2018, 29, 3638–3648 (Figure 
2.1).35  
 
Figure 2.1. Rational design of lipidated-siRNA bioconjugates with Linear, V-shape and Y-
branch GRP silencing siRNAs. Figure reproduced with permission from: Shah, S.S.; Cultrara, 
C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct 
Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated 
Chaperones in Prostate Cancer Cells. Bioconjugate Chem., 2018, 29, 3638–3648.35 
 
2.4. Results and Discussion 
2.4.1 Solid-Phase Bioconjugation  
The synthetic siRNA bioconjugates described in this chapter (Table 2.1) are based on the 
sequence compositions used for silencing GRP-75, 78, and 94 expressions in human cancer 
cells.12,13 The linear, V- and Y-shaped RNA templates bearing the nucleophilic 5’-
hexamethylene amino linker within the antisense (A) or sense (S) strands were synthesized by 




procedures,12,13 RNA synthesis on a controlled pore glass support also enabled the incorporation 
of an orthogonally protected 5’-OLv 2’-OMMT ribouridine phosphoramidite as branchpoint 
synthon. Selective deprotections and RNA synthesis facilitated the production of the V- and Y-
shape RNA templates on solid supports. Following RNA synthesis, an O-(1H-6-
chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, HCTU-based 
peptide (amide) coupling reaction was designed and optimized for the incorporation of 
hydrophobic modifiers (i.e., fatty acids) by solid phase RNA bioconjugation, which has been 
found to be useful for the incorporation of hydrophobic molecules onto oligonucleotide strands.36 
More specifically, short and long-chain (C12-C18) fatty acids with saturated, unsaturated, and 
polyunsaturated long chain alkyl groups were coupled onto the amino-linked RNA template 
strands using HCTU as activator, N, N’-diisopropylethylamine (DIEA) as base and N, N’-
dimethylformamide (DMF) as reaction solvent (Scheme 2.1). Following solid phase 
bioconjugation, RNA samples were cleaved and deprotected from the solid support and analyzed 
by RP IP HPLC to determine reaction conversions. The conjugation reactions proceeded with 
good product conversions (52-75%) in the case of antisense linear RNA functionalization. The 
V- and Y-shape RNA templates were subjected to the HCTU/DIEA coupling reaction for the 
incorporation of palmitic acid which produced good conversions in the case of the V-shape RNA 
bioconjugate (69 %). However, little conjugated product (<5%) was detected in the case of the 
Y-shape RNA template. The latter may be attributed to poor reactivities associated with 
conjugation of fatty acids onto more complex, higher-order RNA templates. We have observed 
similar restrictions with the bioconjugation of fluorescent probes (fluorescein) onto Y-shape 
RNA templates.37 In order to address these limitations, an alternative approach was developed in 




using our established HCTU/DIEA coupling reaction, followed by hybridization to the linear, V- 
and Y-shape antisense RNA templates (Scheme 2.2). This self-assembly approach enabled the 
production of linear, V- and Y-shape GRP targeting siRNAs containing single, double, and triple 
palmitamide incorporations to explore the influence of fatty acid conjugation on the structure-
activity properties of the siRNA bioconjugates.  
 



















1 78A GRP78 5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’ 5.7 5949.6/5949.6 
2 78S GRP78 5’ rArGrU rGrUrU rGrGrA rArGrA rUrUrC rUrGrA rA 3’ 5.7 6104.0/6103.7 
3 94S GRP94 5’-rGrArA rGrArA rGrCrA rUrCrU rGrArU rUrArC rC-3’ 5.5 6068.8/6069.0 
4 75S GRP75 5’-rArCrU rGrArC rUrCrG rGrArG rArArU rArCrA rA-3’ 5.9 6091.8/6092.3 
5 78AC12 GRP78 (Lauric Acid))C12COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’ 17.3 6311.0/6311.1 
6 78AC16 GRP78 (Palmitic Acid)C16COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’ 21.9 6367.3/6367.2 
7 78AC18:1 GRP78 (Oleic Acid)C18:1COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’ 22.5 6394.0/6393.3 
8 78AC18:2 GRP78 (Linoleic Acid)C18:2COOH/5AmMC6/5’ rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU 3’ 21.3 6391.2/6391.2 




2’3’ rCrUrU rCrUrU rCrGrU rArGrA rCrUrA rArUrC rG 5’ 
                                          rU 






                                                                          2’3’-rCrUrU rCrUrU rCrGrU rArGrA rCrUrA rArUrG rG-5’ 
5’-rUrUrG rUrArU rUrCrU rCrCrG rArGrU rCrArG rU-3’5’-rU 






             2’3’ rCrUrU rCrUrU rCrGrU rArGrA rCrUrA rArUrC rG 5’/5AmMC6/C16COOH 
             rU 
             3’5’-rArUrC rArGrA rArUrC rUrUrC rCrArA rCrArC rU-3’ 
19.0 12723.4/12723.3 




14 94SC16 GRP94 C16COOH/5AmMC6/5’-rGrArA rGrArA rGrCrA rUrCrU rGrArU rUrArC rC-3’  20.8 6496.1/6496.3 
15 75SC16 GRP75 C16COOH/5AmMC6/5’-rArCrU rGrArC rUrCrG rGrArG rArArU rArCrA rA-3’ 21.1 6520.1/6519.3 
 
aLinear sequence number 1, 5, 6, 7 and 8 represents antisense (A) RNA sequence and the 
corresponding fatty acid bioconjugate to its complimentary sense (S) sequence 2. V-shaped 
siRNA sequences 10 and 12 contains two siRNA sequences targeting GRP78 and GRP94 mRNA 
to its complimentary sense (S) sequences 2 and 3. Y-shaped RNA sequence 11 contains three 
RNA sequences targeting three different sites of GRP78, GRP94 and GRP75 mRNA to its 
complimentary sense (S) sequences 2, 3, 4 along with 13, 14 and 15 as a palmitic acid 
bioconjugate.  bObtained by RP-IP-HPLC using 0.1 mM TEAA in TEAA with 7-70% MeCN, 
pH: 7.1 over 40 min. cCalculated mass (observed mass) by ESI-MS in negative mode (Novatia 
LLC, Newton, PA). Table reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, 
S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of 
Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in 







Scheme 2.1.  Solid-phase bioconjugation of the amino-linked linear, V-, and Y-Shaped RNA 
templates with various fatty acids to afford the amide-linked fatty acid-RNA bioconjugates. 
Scheme reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; 
Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid 
Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer 









Scheme 2.2. Self-assembly of i. linear, ii. V- and iii. Y-shape multi-palmitamide labeled siRNA 
constructs. Scheme reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; 
Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty 
Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in Prostate 






2.4.2 Analysis and Purification of Fatty acid conjugated RNA Templates. 
Following synthesis, the fatty acid conjugated RNA templates (Table 2.1) were purified 
by analytical Reverse-Phase Ion-Pairing High Performance Liquid Chromatography (RP IP 
HPLC) in ≥90% purities. Further, their identities were confirmed by electrospray ionization mass 
spectrometry (ESI MS) in negative mode using the LC/MS facilities at Novatia LLC (Newton, 
PA). Purified RNA templates with and without fatty acid conjugations were also analyzed by 
denaturing (urea) polyacrylamide gel electrophoresis (PAGE) (Figure 2.2) which confirmed 
sample purities and provided a first indication of the structural influence of the fatty acid groups, 
generating more retained bands compared to the unconjugated RNA templates. This trend 
underscores the potential impact of the fatty acid group in increasing the hydrophobicity, size, 
and structure composition of the functionalized RNA. UV-Visible (UV-Vis) spectroscopy was 





















Figure 2.2. Denaturing PAGE of fatty acid conjugated linear (78AC12, 78AC16, 78AC18:1, 
78AC18:2, 78AC:3), and V-shape (7894VC16) RNA templates and the unconjugated RNA 
controls (linear 78A, V-shape 7894VA, Y-shape 789575YA). Figure reproduced with permission 
from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, 
J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the 










2.4.3 RP IP HPLC analysis of fatty acid conjugated siRNAs 
The fatty acid conjugated RNA samples along with their native RNA templates were 
analyzed by RP IP HPLC with a Symmetry C-18 reverse phase column (4.6 x 250 mm, 5 µm 
particle size) using a gradient elution method of 7-70 % (MeCN in 0.1 M triethylammonium 
acetate, TEAA) over 40 minutes (Figure 2.3). These analytical HPLC conditions were used to 
analyze the amphiphilic trends of the linear RNA templates conjugated with a small set of 
saturated, monounsaturated, and polyunsaturated fatty acids (Scheme 2.1, Samples 1-8) with 
varying chain lengths along with the V-shape RNA bioconjugate (Scheme 2.1, Sample 9). 
However, no detectable fatty acid conjugated product was observed with Y-shape RNA (Scheme 
2.1, Sample 10). RP IP HPLC analyses confirmed greater retention (22.5 min) of the lengthier 
(Sample 3, 78AC18:1) fatty acid conjugated RNA when compared to the shorter (Sample 1, 
78AC12) fatty acid bioconjugate (17.3 min) confirming that increasing fatty acid chain length 
increases hydrophobicity onto the RNA sequence, thus providing greater retention on the reverse 
phase column(Figure 2.3). Alternatively, increasing the degree of unsaturation with the 
polyunsaturated fatty acid-RNA conjugates resulted in the shortest retention times (Sample 5, 
78AC18:3, 20.1 min) when compared to the monounsaturated (Sample 3, C18:1, 22.5 min) and 













Figure 2.3. HPLC chromatogram of linear and V-shaped fatty acid-RNA bioconjugates along 
with their corresponding RNA templates (inset) and retention times (min). Figure reproduced 
with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; 
Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs 
and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate 




It is hypothesized that increasing the cis-double bond character within the polyunsaturated fatty 
acids is expected to minimize their packing arrangement contributing to reduced hydrophobicity 
of the conjugated RNA sequences according to NMR and HPLC data of related saturated and 
unsaturated fatty acid conjugated siRNA.38 Similarly palmitic acid conjugated V-shaped RNA 




to the linear sense strands that were also functionalized with palmitic acid (Samples 6-8, GRP75, 
78, 94 SC16, 20-22 min). Thus, fatty acid chain length and double bond character influences 
RNA hydrophobicity, which in turn may influence RNA hybridization, structure, and biophysical 
properties.  
 
2.4.4 Non-denaturing (native) PAGE analysis of fatty acid conjugated siRNAs 
The purified RNA templates and their complementary RNA strands in their lipidated and 
non-lipidated form were hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM 
EDTA, pH 7.5–8.0) using equimolar concentrations (1.25 µM) of the pairing strands. Samples 
were hybridized by heating the complementary sequences at 95 °C (5 min) followed by slow 
cooling to room temperature (22 °C) for 1 h, and overnight storage at 4 °C. siRNA hybridization 
was confirmed by native, non-denaturing 16% polyacrylamide gel electrophoresis (PAGE). In 
this assay (Figure 2.4A), the native, linear siRNA hybrid (Figure 2.4A, Lane 1) migrated fastest 
on the gel when compared to the related linear siRNA-fatty acid bioconjugates (Figure 2.4A, 
Lanes 2-6). Comparatively to the HPLC analyses (Figure 2.3), linear fatty acid functionalized 
siRNAs displayed a gel migration pattern that was consistent with the lengths of the hydrocarbon 
tails, with the lengthier fatty acids (Figure 2.4A, 78AC16-C18, Lanes 3-6) being most retained 
when compared to the shorter one (Figure 2.4A, 78AC12, Lane 2).  Similar retention trends 
were observed on RP IP HPLC (Figure 2.3). Similarly, the V and Y-shaped RNA templates 
(Figure 2.4A, Lanes 7 and 9) were more retained on the gel when compared to their linear 
counterparts, whereas the palmitamide conjugated V-shape siRNA (Figure 2.4A, Lane 8) was 
also found to be more retained on gel when compared to the corresponding V-shape 




hybridization of the linear, V- and Y-shape motifs, with the linear and V-shape siRNA 
conferring more retained gel migration when conjugated with their corresponding fatty acids. In 
the case of the V- and Y-shape siRNA bioconjugates, linear sense strand palmitamide 
conjugation facilitated the self-assembly and hybridization of the V-and Y-shape siRNA 
(Scheme 2.2). This one-pot self-assembly strategy enabled the rapid formation of V- and Y-
shape siRNA bioconjugates functionalized with a single, double, and triple palmitamides to 
explore the influence of multiple fatty acid groups on siRNA structure and amphiphilicity 
(Figure 2.4B, Lanes 6, 7 and 9-11). In the native PAGE analysis, the linear siRNA hybrid 
control (Figure 2.4B, Lane 1) migrated fastest on the gel, followed by its palmitamide 
bioconjugate functionalized on either sense or antisense strands (Figure 2.4B, Lanes 2 and 3). 
Similarly, the native V- and Y-shaped siRNA hybrids (Figure 2.4B, Lane 4 and 8) also migrated 
fastest on the gel when compared to the palmitic acid conjugated V-shaped RNA template 
(Figure 2.4B, Lane 5) followed by the more retained V-shape siRNA conjugated with a single 
and double palmitamides (Figure 2.4B, Lane 6 and7). For the Y-shape series, analogous 
migration trends were observed on native gel, with the Y-shape RNA template migrating the 
fastest (Figure 2.4B, Lane 8) followed by the palmitamide conjugated RNA template (Figure 
2.4B, Lane 9) and siRNA hybrids incorporating double and triple palmitamides (Figure 2.4B, 
Lanes 10 and 11, respectively). Taken together, the native gel data confirmed the hybridization 
and self-assembly of linear, V- and Y-shape siRNA bioconjugates incorporating single or 







2.4.5. Circular dichroism (CD) analysis of lipidated siRNAs. 
Circular dichroism (CD) spectroscopy was used to investigate whether the fatty acid 
conjugated siRNA hybrids preserved the prerequisite A-type helix geometry for RNAi 
applications.39 The CD spectra (Figure 2.4C) confirmed the A-type structure for the lipidated 
linear, V- and Y-shaped siRNA bioconjugates with a minimum peak at 240 nm and broad 
maxima in between 250-290 nm. Though, small variations in the amplitudes of the molar 
ellipticities at these distinctive wavelengths were observed for the higher-order V- and Y-shape 
bioconjugates representing some perturbation of the fatty acid on siRNA helical geometry.  
 
2.4.6 Thermal Denaturation (Tm) 
The siRNA hybrid thermal stabilities were measured by thermal denaturation (Tm) 
experiments to examine the influence (if any) of the fatty acid groups on siRNA hybridization 
(Figure 2.4D). The Tm data indicates the melting temperature at which 50% of the hybrid 
siRNA will denature to RNA single strands, thereby causing an increase in the observed RNA 
absorption at max: 260nm.40 The melting curves for native and fatty acid conjugated siRNAs 
indicated that the incorporation of various fatty acids generated stable siRNA hybrids (Tm: 60-






Figure 2.4 (A) Native, nondenaturing 16% PAGE of native linear, V and Y-shaped siRNA 
hybrids (Lanes 1, 7 and 9); saturated, unsaturated, and polyunsaturated fatty acid conjugated 
linear siRNA hybrids (Lanes 2-6) along with palmitamide conjugated V-shape siRNA (Lane 8). 
(B) Native, nondenaturing 16% PAGE of native linear, V and Y-shaped siRNA hybrids (Lanes 
1, 4 and 8); palmitamide conjugated linear and V-shaped siRNA (Lanes 2 and 5, respectively); 
palmitamide conjugated linear sense (S) strands hybridized to complementary antisense (A) 
linear, V and Y-shaped RNA templates (Lane 3, 6, 7, 9-11) (C) Circular dichroism spectroscopy 
of linear, V- and Y-shaped siRNAs and their lipid bioconjugates (1.25 µM) in annealing buffer 
(1 mL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5). (D) Thermal denaturation linear, V- 
and Y-shaped siRNAs and their corresponding lipid bioconjugates (1.25 µM) hybridized in 
annealing buffer (1 mL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5). Figure reproduced 
with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; 
Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs 
and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate 




2.4.7. Serum Stability analysis of siRNAs.  
Fatty acids such as palmitic acid have been used to improve siRNA half-life in biological 
serum and stability towards enzymatic digestion.41,42 In order to explore the influence of fatty 
acid conjugation on siRNA serum stability, the palmitamide conjugated linear siRNA hybrids 
with antisense (C16A:S) and sense (C16)1A:S) strand modifiers in the presence of 10% FBS 
revealed improved stability and resistance towards degradation for up to 24 h when compared to 
the native, unconjugated siRNA hybrid (A:S) (Figure 2.5). These results underscore the 
potential therapeutic utility of the fatty acid siRNAs that may lead to long-lasting gene silencing 
activity in biological systems.  
 
 
Figure 2.5. Serum stability study (10% FBS) of linear siRNA control (A1:S1), palmitamide 
conjugated both antisense and sense linear siRNA (C16 A:S and (C16)1A:S). Figure reproduced 
with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; 
Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs 
and Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate 






2.4.8. DLS and TEM analysis of fatty acid conjugated siRNAs  
Dynamic light scattering (DLS), and transmission electron microscopy (TEM) were used 
as instrumental tools to investigate the influence of fatty acid conjugation on siRNA 
morphology, size, structure and aggregation as well as zeta potential values demonstrating 
charge distributions (Figure 2.6 and Table 2.2). TEM images of saturated (Figure 2.6A) and 
unsaturated fatty acid conjugated (Figure 2.6B) to linear siRNAs indicated large, spherical 
aggregates of about 300 nm. DLS measurements of these samples showed multimodal size 
distribution suggesting formation of large aggregates. Zeta potential measurements of these 
samples showed an overall reduction in charge density when compared to the native, 
unconjugated siRNA (Table 2.2). Similarly, palmitic acid conjugated to higher-order V-shaped 
RNA displayed a propensity for aggregation, however, without formation of well-defined 
structures (Figure 2.6C). The palmitic acid conjugated to sense strand formed the linear 
palmitamide conjugated siRNA which formed spherical aggregates of about 300 nm (Figure 
2.6D) similar to the ones observed for the antisense strand functionalized palmitic acid-siRNA 
bioconjugate (Figure 2.6A). The palmitamide conjugated sense RNA strands hybridized with the 
V-shape RNA template to form the V-shape siRNA bioconjugate with double palmitic acid 
incorporations (Figure 2.6E). Similarly, the palmitamide conjugated sense RNA strands 
hybridized with the Y-shape RNA template to form the Y-shape siRNA bioconjugate with triple 
palmitic acid incorporations (Figure 2.6F). These multi-labeled higher-order siRNA 
bioconjugates displayed large irregular amorphous aggregates (> 300 nm). Thus, the 
incorporation of multiple fatty acids within siRNA triggers formation of larger, and typically 
undefined aggregates that may have profound effects on siRNA cell biology.  Furthermore, the 




measurements are provided in Table 2.2, which supports the observed particle characteristics 




Figure 2.6. Representative DLS derived size distribution and corresponding TEM images of (A) 
saturated (C16), (B) unsaturated (C18:3) linear siRNA and (C) palmitic acid (C16) conjugated V 
shaped siRNA bioconjugates. Palmitic acid (C16) conjugated sense strands were used to 
generate the multi-functionalized linear (single), V (double) and Y-shaped (triple) palmitamide-
siRNA bioconjugates (D-F). Figure reproduced with permission from: Shah, S.S.; Cultrara, C.N.; 
Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct 
Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated 





Table 2.2. Particle size and zeta potential measurements of linear, V and Y shaped RNA-fatty 





Particle Size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) DLSa TEM 
Linear Control A1:S1 480 NA 0.502 -15 
Dodecanoic Acid 
Conjugated 
78AC12 600 NA 0.516 -13 
Palmitic Acid Conjugated 78AC16A 370 130 0.507 -14 
Oleic Acid Conjugated 78AC18:1 370 NA 0.538 -10 
Linoleic Acid Conjugated 78AC18:2 690 450 0.610 -8.3 
Linolenic Acid Conjugated 78AC18:3 240 350 0.472 -7.2 
V shaped RNA Control 7894VA:S 760 NA 0.707 -3.6 
Palmitic Acid Conjugated 7894SVC16 280 500-750 0.644 -4.1 
Y-Shaped RNA control 757894YA:S 340 NA 0.580 -6.9 
Palmitic Acid Conjugated 
(Sense) 
78S(C16)1 290 250-424 0.463 -5.9 
Palmitic Acid Conjugated 
(Sense) 
7894SV(C16)2 340 240-450 0.363 -2.4 
Palmitic Acid Conjugated 
(Sense) 
757894SY(C16)3 300 200-230 0.322 -16 
 
. aDLS analysis data presented are triplicate and having a range of standard deviation of 30-100 nm 
in terms of size depending on the type of samples. Table reproduced with permission from: Shah, 
S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, 
D. Direct Transfection of Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-








2.4.9. Biological Activity of siRNA Bioconjugates 
 
Following evaluation of the biochemical and physical properties, the biological activity 
of the fatty acid conjugated linear, V- and Y-shape siRNAs was examined in a PC-3 prostate 
cancer cell line.43 The PC-3 prostate cancer cell line (ATCC® CRL-1435™) was used as a GRP 
overexpressing cell line model to examine the knockdown efficiency of the lipidated siRNA 
constructs.44 The Trans-IT X2® Dynamic Delivery System (Mirusbio®) was used as suitable 
siRNA transfection reagent within the PC-3 cell culture to establish the baseline GRP 
knockdown activity of the unconjugated linear, V- and Y-shape siRNA controls. In this assay, 
the control sequences exhibited potent (60-80%) GRP mRNA knockdown according to RT PCR 
(Figure 2.7A).  Comparatively, the antisense fatty acid functionalized linear siRNAs (Scheme 
2.1, Samples 1-5) transfected directly and without the use of the Trans-IT X2® transfection 
reagent triggered GRP78 mRNA knockdown, albeit to a lesser extent (20-40%) relative to the 
linear siRNA control (80%) transfected with the Trans-IT X2® dynamic delivery system (Figure 
2.7B).  Interestingly, the length of the hydrophobic fatty acid tail and the degree of unsaturation 
did not have any significant impact on siRNA activity. Thus, palmitic acid (C16) which has been 
found to be well tolerated in siRNA applications,19-27 was chosen to functionalize the higher- 
order V- and Y- shape siRNAs for silencing multiple GRPs. In this direct transfection assay, 
GRP78 knockdown (~40%) was noted with the palmitamide conjugated linear, V- and Y-shape 
siRNAs, however, with little effects on GRP75 and 94 mRNA levels (Figure 2.7C). In an effort 
to improve GRP knockdown activity, the palmitamide-functionalized sense strand RNAs were 
hybridized and self-assembled to the complementary antisense strand linear, V- and Y-shape 
RNA templates to afford the siRNA bioconjugates incorporating single, double and triple 




processed in RISC45 were found to improve GRP mRNA knockdown efficacy (~5-60%) upon 
direct transfection within the PC-3 cells (Figure 2.7D); albeit, to a lesser extent when compared 
to the unconjugated siRNAs transfected with the Trans-IT X2® dynamic delivery system (Figure 
2.7A). To provide some rationale for this discrepancy, a cell uptake assay was performed by flow 
cytometry (Figure 2.8). To assess the influence of fatty acid conjugation on siRNA transfection 
efficacy the lipidated siRNA bioconjugates were compared with native, unconjugated siRNA 
transfections with the Trans-IT X2® dynamic delivery system. In this assay, linear, sense strand 
RNAs were functionalized with either palmitic acid or fluorescein isothiocyanate (FITC) 
functioning as reporter probe and hybridized to complementary antisense linear, V- and Y-shape 
RNA templates to afford the multi-labeled siRNA bioconjugates. Flow cytometry revealed 
partial (6 h) cell uptake of the palmitamide-functionalized siRNAs. Comparatively, the native 
siRNAs transfected with the Trans-IT X2® dynamic delivery system maintained FITC cell 
signaling up to 24 h. Thus, partial cell uptake is likely a contributing factor in the modest GRP 
mRNA knockdown (KD) effects observed for the palmitamide-functionalized siRNAs. This may 
be in part due to the larger size aggregates (≥ 300 nm) observed from the DLS and TEM studies 
which may altogether restrict cell permeability.46,47 Additional hydrophobic or amphiphilic 
carriers may be explored in future studies to help improve cell uptake of the functionalized 













Figure 2.7. qRT-PCR analysis of GRP mRNA levels in PC-3 cells following (A) transfection of 
linear, V and Y shaped siRNAs with the Trans-IT X2® dynamic delivery system, (B) direct 
transfection of saturated, unsaturated and polyunsaturated fatty acid-siRNA bioconjugates, (C) 
direct transfection of palmitamide conjugated linear, V and Y-shaped siRNA bioconjugates, (D) 
direct transfection of linear, V and Y-shaped siRNA bioconjugates respectively containing a 
single, double and triple palmitamides. Target mRNA levels are relative to a control siRNA and 
represented as the mean fold change  SD of 3 separate trials. *P<0.05 and ***P <0.001 in PC3 
cells for GRP78 KD. Figure reproduced with permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, 
S.D.; Patel, M.R.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. Direct Transfection of 
Fatty Acid Conjugated siRNAs and Knockdown of the Glucose-Regulated Chaperones in Prostate 


















Figure 2.8. Time dependent (6-24 h) flow cytometric analysis of linear, V and Y shaped FITC 
labeled siRNAs transfected with the Trans-IT X2® dynamic delivery system (A-C). Direct 
transfection of linear, V- and Y-shape FITC-labeled siRNA containing single (D-F) and multiple 
(G-I) palmitamides within the PC-3 prostate cancer cell line. Figure reproduced with the 
permission from: Shah, S.S.; Cultrara, C.N.; Kozuch, S.D.; Patel, M.R.; Ramos, J.A.; Samuni, 
U.; Zilberberg, J.; Sabatino, D. Direct Transfection of Fatty Acid Conjugated siRNAs and 
Knockdown of the Glucose-Regulated Chaperones in Prostate Cancer Cells. Bioconjugate 





2.5. Conclusions  
        In conclusion, short and long-chain fatty acids containing saturated, unsaturated and 
polyunsaturated long chain hydrocarbon groups were successfully incorporated within the GRP-
silencing siRNAs by solid phase RNA synthesis. The siRNA-fatty acid bio-conjugates were 
characterized according to their structural and biophysical properties which revealed amphiphilic 
aggregates with stable hybrid and serum stabilities as well as A-type helical secondary structures 
applicable to RNAi activity. Their biological activity in a metastatic (PC-3) prostate cancer cell 
line revealed partial cell uptake, which contributed to modest RNAi activity when compared to 
the siRNA controls, likely due to the formation of large, aggregated particles. Nonetheless, the 
solid-phase RNA bio-conjugation approach reported in this study provides an important entry 
point for the incorporation of various hydrophobic and amphiphilic functional groups onto 
higher-order, multifunctional siRNA constructs. This strategy may enable the development of 
new generation RNAi molecules for screening important oncogene targets and for improving 
cancer gene therapy applications. 
  
2.6 Experimental Section 
2.6.1 Methods and Materials 
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich and 
VWR and used as received. Solid phase RNA synthesis reagents were obtained from 
ChemGenes or Glen Research Inc. and used without further purification. Analytical thin-layer 
chromatography (TLC) was performed on aluminum-backed silica gel plates (Merck 60 F254). 
TLCs were visualized under UV shadowing (260 nm) or staining (10% H2SO4/MeOH). 
Compound purification using silica gel chromatography was performed on 230-400 mesh silica 




measured by direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-
source in positive mode using 50/50 v/v MeOH/H2O at a flowrate of 0.5 mL/min. Nuclear 
magnetic resonance spectra (1H, 13C, 31P COSY NMR) were recorded on a Varian NMR AS500 
spectrophotometer. NMR spectra were obtained at ambient temperature using an indirect pulse 
field gradient (ID-PFG) probe. The obtained data was processed using VNMRJ software (version 
2.2). Materials for cell biology were obtained from Thermofisher Scientific, Cell Signaling, Bio- 
legend, Mirus and Invitrogen Life Technologies. 
 
2.6.2 Solid-Phase Oligonucleotide Synthesis 
Synthesis of alkyl (C6) amino linker GRP78 antisense RNA (5’-AUC AGA AUC UUC 
CAA CAC U-3’) and sense RNA (5’- AGU GUU GGA AGA UUC UGA U -3’) were performed 
on a 2000 Å UnyLinker controlled pore glass (CPG) support (ChemGenes) using a 1 µmol scale 
automated synthesis cycle on an ABI 3400 DNA synthesizer. All phosphoramidites were 
dissolved in anhydrous MeCN yielding 0.15 M solutions. The coupling times were 5 minutes 
using 0.25 M 5-ethylthiotetrazole (ETT) in MeCN as the activator. The detritylation times were 
set to 2 min using a solution of 3% dichloroacetic acid in CH2Cl2 (DCM). Capping and oxidation 
steps were performed using a mixture of acetic anhydride/N-methyl imidazole in MeCN and a 
solution of 0.01 M iodine in pyridine/THF/H2O respectively. Following synthesis, 
oligonucleotides were cleaved from the CPG and deprotected with NH4OH: EtOH (3:1 v/v) for 
16 hours at 55 ºC. The crude oligonucleotides were evaporated to dryness and re-suspended in a 
mixture of 1:1.5 v/v DMSO:triethylaminetrihydrofluoride(TEA:THF) (250µL) to complete the 
2’-desilylation reaction at 65 °C for 2 h. The crude RNA was precipitated from the reaction 
mixture with 3 M NaOAc (35µL) in n-BuOH (1 mL). Precipitation was completed in a -80°C 




a solid white pellet. Crude oligonucleotides were re-suspended in autoclaved water (1 mL) and 
the yields were determined by UV absorbance measurements at 260 nm. Crude RNA was 
purified by reverse-phase HPLC on a Waters 2695 Alliance system equipped with a 
Symmetry/XTerra RP-C18 reverse phase column (4.6 x 250 mm, 5 µm particle size) and gradient 
elution method of 7-70% MeCN in 0.1M TEAA over 40 minutes. 
 
2.6.3 Solid-Phase RNA Bioconjugation 
The RNA bioconjugates were produced on solid-phase, by combining the fatty acids (7 
mg, 27.3 µmol, 25 eq) with the oligonucleotide-bound resin (0.106 µmol,). A coupling reagent 
(HCTU, 10 mg, 27.3 µmol, 25 eq) was added, and the mixture was suspended in minimum DMF 
(1 mL) and a base (DIEA, 8 µL, 50 eq) was added to initiate the reaction. Reactions were 
conducted in screw-cap Eppendorf tube and performed overnight (16 hrs.) at room temperature 
on a shaker. The CPG was subsequently washed with DMF/DCM/MeOH and dried in vacuo. 
The fatty acid oligonucleotide-bound resin was cleaved and deprotected using NH4OH:EtOH 
(3:1 v/v) for 16 hours at 55 ºC. The crude oligonucleotides were evaporated to dryness and re-
suspended in a mixture of 1:1.5 v/v DMSO: triethylaminetrihydrofluoride (250 µL) to complete 
the 2’-desilylation reaction at 65 °C for 2 hours. The crude RNA bioconjugates were precipitated 
from the reaction mixture with 3 M NaOAc (35 µL) in n-BuOH (1 mL).  Precipitation was 
completed in -80°C freezer 30 min prior to centrifugation (~10,000 rpm, ~5 minutes) leaving the 
crude oligonucleotides as a solid white pellet. The fatty acid RNA bioconjugates was extracted in 
autoclaved water (1 mL), quantitated by UV-Vis spectrophotometry, analyzed, and purified by 






2.6.4 UV-Vis Spectroscopy 
Following cleavage and deprotection, samples were evaporated to dryness on a Speedvac 
concentrator and then re-suspended in 1 mL autoclaved deionized water for analysis. Optical 
absorption spectra were acquired with a HP 8452A Diode Array UV-Vis spectrophotometer. 
Absorption measurements were recorded in between 210-310 nm for RNA samples, which were 
quantified according to the Beer-Lambert law. 
 
2.6.5. Reverse Phase Ion Pairing High Performance Liquid Chromatography (RP 
IP HPLC) 
The crude RNA templates were analyzed by Reverse Phase Ion Pairing High 
Performance Liquid Chromatography (RP IP HPLC) to determine crude purities. Briefly, HPLC 
analyses (~0.1 OD) and purifications (1 OD) were performed on a Waters 2695 Alliance 
Separations Module. Crude RNA templates were dissolved in autoclaved water (1 mL) and 
injected into a Waters Symmetry/XTerra RP C18 reverse phase column (4.6 x 250 mm, 5 µm 
particle size) heated at 60 °C. HPLC analyses and purifications were conducted using a gradient 
of 7-70% eluent C (100% acetonitrile) in eluent A (0.1 M triethylammonium acetate) with a flow 
rate of 1 mL/min, run times of 40 minute and with absorbance detection at 260 nm using a 
Waters 2489 UV/Visible detector. Retention times (min.) and peak areas (% area) were 
integrated with Empower II software and used to confirm RNA purities >90% following sample 
purifications. 
 
2.6.6 Electrospray Ionization Mass Spectrometry (ESI MS) 
All oligonucleotides (0.1-0.4 µM) were dissolved in Millipore water (1 mL) and all the 




on an Oligo HTCS LCMS system equipped with ESI/MS in negative mode. The data was 
processed by a ProMass software. Theoretical molecular weights were calculated using IDT 
mass analyzer https://www.idtdna.com/calc/analyzer. 
 
2.6.7 Hybridization of fatty acid-siRNA bioconjugates 
Equimolar concentrations of fatty acid-RNA bioconjugates and complementary RNA 
were combined with 15 μL of annealing buffer (10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM 
EDTA) in a 1.5 mL screw-cap Eppendorf tube. The mixture was vortexed briefly and placed on a 
standard heat block at 95 ± 1 °C for 5 minutes. The samples were then allowed to slowly cool to 
room temperature before placing in a 4 °C fridge for 24 h. before further hybrid analysis. 
 
2.6.8 Native Polyacrylamide Gel Electrophoresis (PAGE) 
Hybrid siRNA samples (as described above) were removed from the fridge and diluted 
with 15 μL 30% sucrose loading buffer (30% sucrose in 5X TAE buffer). The hybrid samples 
were analyzed using 16% native PAGE. Gels were run at 500 V (60 W) for 3-4 h and visualized 
under short wave UV light. Gels were subsequently placed in a Stains-All® (Sigma) solution (25 
mg S8 Stains-All®, 50 mL isopropyl alcohol, 25 mL formamide, 125 mL water). After 2 h, gels 
were removed from the Stains-All® solution and exposed to light to de-stain. 
 
2.6.9 Circular Dichroism (CD) Spectroscopy 
Annealed siRNA samples (1.25 μM) were diluted to 1 mL with annealing buffer and 
transferred to fused quartz cells with a 1 cm path length and maintained within the cell holder at 
RT under N2 for 10 minutes prior to spectral acquisition. Spectra were collected using an Olis 
RSM CD 1000 spectrophotometer as an average of three scans. Spectra were analyzed between 




correcting by subtracting the buffer followed by smoothing the data points. The data was then 
exported onto Windows Excel™ spreadsheet software for plotting the CD spectra as changes in 
molar ellipticities with increasing wavelengths. 
 
2.6.10 Thermal Denaturation (Tm) 
Annealed siRNA samples (1.25 μM) in annealing buffer were transferred to a fused 
quartz cells with a 1 cm path length and maintained within the cell holder at RT under N2 for 10 
minutes prior to spectral acquisition. Spectra were measured on a CARY 3E, UV-Vis 
spectrophotometer equipped with a temperature controller regulating the changes in 
hyperchromicities at 260 nm with increasing temperatures (20-80°C at 1 °C/min) under N2. The 
melting temperatures (Tm) were calculated from the first derivative plots of the melting curves, 
representing the temperature at which 50 % of the duplex has denatured to the corresponding 
single strands. This data was exported into an Excel™ spreadsheet for plotting the Tm curves.  
 
2.6.11 Dynamic Light Scattering (DLS)  
A Malvern Zetasizer, Nano-ZS (Malvern Instruments, UK) employing a 173° scattering 
angle and a 4mW incident He-Ne laser (633 nm) was used to measure the particle sizes 
(hydrodynamic diameter), size distributions and zeta potentials of the siRNA hybrid control and 
siRNA-fatty acid bioconjugates. Samples were measured in triplicates at 25 oC. All samples were 
loaded into folded capillary cells (DTS1070) equipped with electrodes on both sides to allow 
measurement of their zeta potentials and by extension, the stability and degree of aggregation. 
Particle suspensions with highly positive or highly negative zeta potentials are considered stable 
because the electrical repulsion between the particles tends to counter the van der Waals forces 




2.6.12 Transmission Electron Microscopy (TEM) 
TEM analyses of the linear, V and Y-shaped siRNA bioconjugates were performed with a 
JEOL 1200EX Transmission Electron Microscope (JEOL Ltd, Japan) at an accelerating voltage 
of 80 kV. A mixture of 1:1 volume ratio 1% uranyl acetate and sample suspension were prepared 
and 10 µL of this solution placed on a TEM carbon-film-coated copper grid of 300 mesh 
(Electron Microscopy Sciences Inc., Hatfield, PA). Each sample was allowed to sit for five 
minutes on the grid before wicking the excess liquid followed by storage of one week to allow 
the samples to dry. Images were taken with a SIA-L3C CCD camera (Scientific Instruments and 
Applications, Inc.) using the software Maxim DL5 (Diffraction Limited, Ottawa, Canada). 
 
2.6.13 Serum Stability Assay 
siRNA hybrid samples (A:S, C16A:S and A:S(C16)1) were hybridized using the protocol 
described in section 2.6.7 in annealing buffer. An aliquot (50 µL, 30 µM) was added to a 10% 
FBS solution (50 µL in phosphate buffer). The mixtures were incubated at 37 ºC and periodically 
(0 – 48 h) sample aliquots (15 µL) were removed, frozen at -80 ºC prior to analyses. Samples 
were thawed to room temperature (22 ºC) and diluted by 30 % sucrose loading buffer and 
analyzed on a 16% native, non-denaturing PAGE for 2.5 h. The gel was then visualized with a 
Stains-All (Sigma-Aldrich™) solution.  
 
2.6.14 Cell Culture  
Prostate cancer cell line PC-3 (ATCC® CRL-1435™) was cultured in RPMI-1640 
complete growth medium supplemented with 10% (v/v) fetal bovine serum (FBS), and 1% (v/v) 
penicillin/streptomycin (P/S) under 5% CO2 at 37 ºC. For passaging, PC-3 cells were detached 




2.6.15 siRNA Transfections in PC-3 Cells and Flow Cytometry 
 
PC-3 cells were seeded at a density of 9.0 x 104 cells/well, were plated in 24-well culture 
plates containing RPMI complete culture media with 10% FBS. Cells were cultured in a 
humidified incubator set at 37 ºC with 5% CO2. Prior to transfections, the cocktail and control 
siRNA hybrids (7.5 µL, 10 µM, in Opti-MEM, 133 µL) were mixed with the transfection reagent 
(TransIT-X2® Dynamic Delivery System, 9 µL, in Opti-MEM, 250 µL) according to the 
manufacture’s recommendation and the fatty acid–siRNA bioconjugates were transfected 
directly with final concentration of 50 nM. The mixtures were incubated (15 min, 22 ºC) then 
added to the PC-3 cell culture and incubated at 37 ºC with 5% CO2 over a three-day (72 h) 
period. Samples were tested at 3, 6 and 24 h post-transfection to determine internalization 
efficiency. Cells were removed from the well using trypsin and diluted in RPMI-1640 media. A 
Cytomics FC 500 flow cytometer was used for determining time dependent cell uptake. 
 
2.6.16 mRNA Isolation and Gene Knockdown via Quantitative Real-Time 
Polymerase Chain Reaction (qRT-PCR)  
Total mRNA was isolated following transfection (48-72 hr) from TriZol (Ambion) 
preserved cells using a TriRNA Pure Kit (Geneaid), following the manufacturer’s instructions. 
The collected mRNA was then quantitated on a Qubit 3.0 fluorimeter using the Qubit Broad 
Range (BR) assay kit (Thermo Fisher Scientific). mRNA (200 ng) was reverse transcribed into 
cDNA using a high-capacity cDNA kit (Applied Biosystems). RT-PCR was performed using 
pre-developed TaqManTM gene expression primer-probes for GRP78 (assay ID 
Hs99999174_m1), GRP94 (assay ID Hs00437665_g1), GRP75 (Hs00269818_m1), and GAPDH 




on a StepOnePlus (Applied Biosystems). Fold changes were calculated with the ΔΔCt method 
using GAPDH as endogenous control and the negative siRNA as the control sample. 
 
2.6.17 Statistical Analysis  
 
         All data were plotted and analyzed using the GraphPad Prism software, V 7.0d (La Jolla, 
CA). Each experiment was performed in triplicates (N=3). Data is represented as the mean  SD. 
Comparisons between two groups were analyzed using unpaired Student’s t-tests. A probability 
(P) value of less than 0.05 was considered statistically significant. 
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Chapter 3: Bifunctional Au-templated RNA Nanoparticles Enable Direct 
Cell Uptake Detection and GRP75 Knockdown in Prostate Cancer 
 
3.1 Abstract 
Nucleic acids templated on gold (Au) surfaces have led to a wide range of functional 
materials ranging from microarrays, sensors, and probes as well as applications in drug delivery 
and treatment. In this thesis chapter, we describe a simple and novel method for templating 
amino-functionalized RNA onto Au surfaces and their self-assembly into small, discrete 
nanoparticles for gene therapy applications in prostate cancer cells. In our method, sample 
hybridization with a complementary RNA strand with and without a fatty acid (palmitamide) 
produced palmitamide-functionalized double-stranded RNA on the Au surface. The resulting 
Au-RNA particles were found to be stable under reducing conditions according to UV-Vis 
spectroscopy. Sample characterization by DLS and TEM confirmed self-assembly into primarily 
small (~10-40 nm) spherical-shaped nanoparticles expected to be amenable to cell biology. 
However, fluorescence emission (λexc: 350 nm, λem: 650 nm) revealed radiative properties 
associated with gold nanoparticles, which restricted cell biology applications (i.e. cell uptake, 
and cytotoxicity) due to limitations with the emission/scattering detection of gold nanoparticles 
by flow-cytometry and high content screening microscopy. Introduction of fluorescein within the 
Au-RNA particles produced a bifunctional probe, in which fluorescein emission (λexc: 494 nm, 
λem: 522 nm) facilitated cell uptake detection, in a time-dependent manner. The dual 
encapsulation-release profiles of the fluorescein-labeled Au-RNA particles were validated by 
time-dependent UV-Vis spectroscopy and spectrofluorimetry. These experiments respectively 
indicated an increase in fluorescein absorption (λabs: 494 nm) and fluorescence emission (λem: 




Au-functionalized siRNA particles in prostate cancer (PC-3) cells resulted in GRP75 
knockdown, which led to detectable levels of cell death in the absence of a transfection vector. 
Thus, the formulation of stable, small, and discrete Au-RNA nanoparticles may prove to be 
valuable bifunctional probes in the theranostic study of cancer cells. 
3.2 Introduction 
The advancement of RNA nanomaterials has led to the development of new molecular 
tools capable of screening, detecting, and treating a wide range of malignancies, including 
cancer.1-4 In the fight against cancer, RNA nanomaterials functioning as precision nanomedicines 
have improved target specificity, cell uptake, and anti-cancer activity relative to non-specific and 
toxic chemotherapy and radiative treatment regimens. More specifically, in recent years, metal 
nanoclusters have emerged as a promising class of theranostic agents due to their unique metal 
core and surface-layer properties which facilitate functionalization with bio-active probes for 
bioimaging, biosensing, and therapeutic applications.5-13 Moreover, the recent generation of gold 
(Au) functionalized RNA has enabled the self-assembly of stable RNA nanoparticles that have 
been found to be compatible with cell biology applications.14 These have included the structural 
assembly of molecular beacons,15 and sensors for nucleic acid detection,16 microarrays for gene 
screening and sequencing methods,17 controlled and targeted RNA delivery for gene therapy in 
cells, tissues, and animal models.18-21 Of specific interest, recent studies have demonstrated that 
Au nanoparticles, functionalized with polyethylene glycol (PEG) and polyethyleneimine (PEI), 
respectively applied as biocompatible and condensing agents for RNA cell uptake, along with 
transferrin (Tf) and folate (FA) as cell-targeting ligands have been effectively used to deliver 




siRNA nanoparticles exhibited notable intracellular silencing of the RelA oncogene when 
compared to the non-targeted formulation, suggesting that Au-siRNA nanoparticles may have 
potential in the detection and treatment of PCa. It was also found to be the case with PEI-
functionalized Au nanoparticles bearing anisamide (AA) as targeting ligand.23 In this study, 
siRNA delivery into PC-3 PCa cells resulted in significant (~70%) knockdown (KD) of the RelA 
oncogene in a cell-line dependent manner which expresses the sigma (σ) receptor on the cell 
surface in the absence of serum media. Serum was found to obstruct the requisite ligand-receptor 
interaction required for cell uptake and KD activity. In addition to their theranostic activities, 
Au-functionalized siRNA nanoparticles have also been shown to 1) have enhanced serum 
stability when compared to their native siRNA counterparts,24 2) serve as stimuli-responsive 
materials for controlled siRNA intracellular release under glutathione-reducing cytosolic 
conditions,25 and 3) possess desirable radiative and photothermal properties into the near-infrared 
(NIR) region which is advantageous in producing local heating and cavitation of endosomes, 
resulting in siRNA intracellular escape.26 This is in contrast to siRNA-based formulations which 
are not amenable to cell transfection and in vivo delivery of siRNA due to their limited 
capabilities of 1) condensing and releasing siRNA at the target site for RNAi silencing activity, 
2) conferring serum stability, 3) generating small, discrete and neutral nanoparticle formulations 
for efficient cell uptake and 4) limiting off-target silencing and toxicity effects.27-29 Thus, Au-
siRNA formulations have resulted in successful gene silencing applications and may form the 
basis for the development of potent therapeutic interventions against malignant oncogene targets. 
Glucose-regulated proteins (GRPs), are a class of chaperone proteins that serve as the 
main regulators of the unfolded protein response under physiological and pathological stress 




folding activity, in the mitochondria, they interact with pro-apoptotic executors that regulate cell 
survival/death responses and at the cell surface, the direct signal transduction. Moreover, GRPs 
have been found to be over-expressed and cell surface localized in a wide range of cancer types, 
where they regulate cancer initiation, proliferation, adhesion, and invasion which contributes to 
metastatic spread and chemoresistance. Thus, the GRPs have been classified as clinically 
relevant biological markers in cancer detection and treatment.30 Among the GRPs, the Glucose 
Regulated Protein of 75 kilodaltons (GRP75/Mortalin) has been classified as a homolog of the 
Heat Shock Protein of 70 kilodalton (HSP70) and functions primarily as a mitochondrial 
chaperone where it regulates cell growth and survival related to mitochondrial-dependent cell 
death pathways.31 GRP75 is localized in the ER where it assists in protein folding and at the 
plasma membrane where it confers cell survival from complement-dependent cytotoxicity (CDC) 
pathways.32 Moreover, GRP75 has been strongly associated with tumor resistance, survival, and 
proliferation, making it a clinical target for the detection and treatment of certain tumor types.33-
36 For example, GRP75 has been found to be overexpressed in tumors of the colon, liver, brain, 
breast, and skin, where it functions as an important regulator of tumor cell growth and 
survival.37,38 In PCa, GRP75 has been detected by western blot and correlated with a visceral 
metastasis-derived (PC-3M) cell line.39 Knockdown or inhibition of GRP75 was found to reverse 
its pro-survival effects resulting in tumor apoptosis.40-42 Therefore, therapeutic targeting of 
GRP75 has potential anti-cancer implications. 
 
3.3 Chapter Objectives 
In this chapter, our objective is to develop a methodology that improves cell-uptake and 
GRP75 knockdown efficacy in PCa cells using Au-siRNA nanoparticle-formulations. Towards 




linear, branch, and hyper-branch RNA templates for their self-assembly into higher-order siRNA 
nanostructures.43,44 Significantly, these constructs silenced GRP75, GRP78, and GRP94 
expressions in the liver (HepG2), endometrial (AN3CA), cervical (HeLa), and breast (MDA-
MB-231) cells resulting in synergistic anti-cancer effects. Recent efforts to expand the scope and 
functionality of the siRNA nanostructures resulted in the formulation of fluorescently labeled45 
and fatty acid conjugated46 constructs that exhibited modest KD and toxicity effects in PCa cells 
in the absence of a transfection vector. Overcoming this siRNA delivery challenge is a critical 
requirement for successful cell-based gene therapy applications.  
To improve the cell uptake and theranostic utility of our multi-functional siRNA 
nanostructures in PCa cells, this thesis chapter will describe the rational design, synthesis, 
characterization, and biological evaluation of newly assembled bifunctional Au-templated RNA 
nanoparticles. The synthetic method for the formulation of Au-RNA particles will be based on a 
novel bottom-up approach for nucleating synthetic double-stranded (ds) RNA in which the 
antisense (A1) strand bearing a reactive alkylamino linker will used to template RNA onto the 
surface of reduced Au particles. The complementary sense (S1) strand will be functionalized 
with and without a palmitamide (C16) fatty acid group or fluorescein isothiocyanate (FITC) as 
fluorescent (FL) reporter to generate the bifunctional Au-templated siRNA particles targeting the 
GRP75 oncogene (Figure 3.1). This is in contrast to the commonly used alkylthio modifiers on 
DNA and RNA for Au surface immobilization studies.47,48 Comparatively, this novel method 
involves the alkylamino linkers which are anticipated to provide the dual advantage of 
functionalization with a biological probe on the S1 strand and using the A1 strand for assembly 
onto the Au surface to generate the purported bifunctional Au-RNA particles (Figure 3.1B). The 




silencing GRP75 expression in PCa (PC-3) cells (Figure 3.1A).44-46 The formulation will then be 
characterized by a combination of UV-Vis and fluorescence spectroscopy which will provide 
insights into the photophysical properties, specifically related to the fluorescence 
excitation/emission profiles for Au (λexc: 350 nm, λem: 650 nm) and FITC (λexc: 494 nm, λem: 522 
nm). In collaboration with Drs. Uri Samuni and Jorge Ramos at Queen’s College, City 
University of New York, the relative sizes, shapes, uniformities, and charge distributions of the 
Au-siRNA particles will be determined by a combination of dynamic light scattering (DLS) and 
transmission electron microscopy (TEM). Small particles, uniform, and of neutral charge are 
anticipated to be amenable to cell biology applications. In collaboration with Drs. Christopher 
Cultrara and Jenny Zilberberg at the Center for Discovery and Innovation, Hackensack-Meridian 
Health, the cell-uptake, GRP75 KD, and cell death effects in PC-3 prostate cancer cells will be 
evaluated. This thesis chapter thus describes our published collaborative work, highlighting the 
formulation, characterization, and biological evaluation of GRP75 silencing Au-siRNA 
formulations for anti-cancer applications.49  
Texts and figures described in this thesis chapter have been adapted with permission from our 
publication Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J 













Figure 3.1. Rational design of (A) GRP75 targeting siRNA bioconjugates and (B) bifunctional 
Au-templated RNA particles. Figure reproduced with the permission from: Shah, S.S.; Cultrara, 
C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-
217.49  
 
3.4 Results and Discussion 
3.4.1. Synthesis of Bifunctional Au-templated RNA particles 
The rational design and synthesis of self-assembled Au-RNA nanoparticles were based 
on templating linear RNA sequences functionalized with a reactive hexamethylene amino linker 
at the 5’-termini of the antisense (A1) or sense (S1) single strands onto the Au surface under 
reducing conditions. This was followed by self-assembly with the complementary strands to 
generate the GRP75 targeting siRNA-Au particle formulation. Furthermore, adopting our 




palmitic acid (C16) or fluorescein isothiocyanate (FITC). The biological probes were used 
respectively for facilitating cell uptake and tracking biological activity in cells. Following 
synthesis of the functionalized RNA strands, the samples were cleaved, deprotected from the 
solid support, and purified by RP IP HPLC with purities >90% for the generation of the 
bifunctional Au-RNA particles. 
The formulation strategy for the bifunctional Au-RNA particles is based on a newly 
developed bottom-up approach, in which the 5’amino-functionalized A1 RNA single strands 
were expected to facilitate in-situ nucleation and growth of Au-RNA nanoparticles using mild 
reducing conditions (citric acid) in RNA annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM 
EDTA, pH: 7.1). More specifically, this novel formulation approach required reduction of gold 
salts (hydrogen tetrachloroaurate (III) trihydrate, HAuCl4.3H2O, 0.01 M), with a mild reducing 
agent (trisodium citrate trihydrate, Na3C6H5O7.3H2O, 0.1%) along with hybridization of 
equimolar concentrations (1.25 µM) of the complementary RNA strands (A1+S1) in RNA 
annealing buffer. This multi-component one-pot reaction was heated at 95 °C for 5 minutes 
followed by slow cooling to room temperature (22 °C) and overnight storage in the fridge (4 °C) 
before sample analysis (Scheme 3.1). In this manner, the Au-RNA formulation was anticipated 
to consist of a core of metallic (Au) nanoparticles decorated with surface functionalized GRP75-















Scheme 3.1. Formulation strategy for the generation of bifunctional Au-RNA particles. Scheme 
reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; 
Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49  
 
3.4.2. Characterization of bifunctional Au-RNA particles 
The physicochemical properties of the bifunctional Au-RNA particles were assessed by 
UV-Vis spectroscopy, to determine the characteristic absorption profiles of the RNA (λmax: ~260 
nm) and metallic (Au) (λmax: ~530 nm) components (Figure 3.2A). A characteristic color change 
from a clear, transparent solution to a deep red color was initially observed and attributed to the 
reduction of the Au salts (HAuCl4; λmax: ~302 nm) and the appearance of the characteristic 
surface plasmon absorption band of Au nanoparticles (λmax: ~530 nm).47 These characteristic 
absorption bands provide supportive evidence for the formation of stable Au-RNA particles, 
without any observable sample precipitation for weeks at 4 oC. However, further characterization 
using UV-Vis spectroscopy and DLS will be required to confirm sample stability. Interestingly, 
conjugated dsRNA bearing palmitamide (C16) or FL (FITC) labels on the S1 strands produced 
stable bifunctional Au-RNA particles, validating the reactivity of the free 5’-alkylamino termini 




the complementary S1 strands provide further functionalization with bio-active probes. This is in 
contrast to the commonly used alkylthio modifiers on DNA and RNA for Au surface 
functionalization, which is prone to cross-linking under oxidative conditions due to its highly 
reactive nature, and may thus restrict the extent of functionalization of bio-active probes on the 
Au surface.48 Alternatively, our new method of using the alkylamino linkers on the A1 or S1 
strands offers the dual advantage of conjugation with a biological probe on the S1 strand and 
functionalizing the A1 strand onto the Au surface to generate the putative bifunctional Au-RNA 
particles.  
 
Figure 3.2.  A) UV-Vis and B) Fluorescence spectra of Au-RNA particle formulations along 
with their dsRNA hybrid controls (75A1S1, NSA1S1). The inset provides a depiction of sample 
color changes (clear-to-deep red) without noticeable precipitation which is indicative of stable 
Au-RNA particles. C16 refers to palmitamide conjugation, 75 refers to GRP75 silencing siRNA, 
A1, S1 refers to the antisense, and sense dsRNA strands, NS refers to the non-specific dsRNA 
control. FITC (FL) or C16 (palmitamide) conjugation of the sense (S1) strand. Figure reproduced 
with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; 
Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49  
 
Fluorescence emission spectroscopy was also performed to evaluate the fluorescence 
emission intensities of the Au-RNA particles (Figure 3.2B). The fluorescence emission 




probe. Au-RNA particles required UV excitation (λex: ~350 nm) in order to provide an emission 
(λem: ~650 nm) in the red region of the visible spectrum. Meanwhile, the FITC-labeled Au-RNA 
particles displayed characteristic excitation (λex: ~495 nm) and emission (λem: 522 nm) bands for 
the (FITC) fluorophore, which were observed well into the visible region of the electromagnetic 
spectrum. The latter is a desirable property for cell biology studies which avoids the use of UV 
lasers that may be detrimental to cell viability. Therefore, the bifunctional FITC-labeled Au-
RNA particles were selected to determine cell uptake within PC-3 prostate cancer (PCa) cells.  
Prior to biological studies, DLS and TEM were used to determine the sizes, shapes and 
surface charge densities (zeta-potential) of the Au-RNA particles. Previous studies have shown 
that large, polyanionic aggregates of RNA particles abrogated their cell uptake and biological 
activity.28,50 Therefore, DLS and TEM were conducted in order to determine whether the Au-
RNA particles formed small, discrete, and neutrally charged nanoparticles that may facilitate cell 
uptake for biological activity in the absence of a transfection reagent. According to the DLS data, 
the linear RNA hybrid controls (75A1S1, NSA1S1, and 75A1S1C16) were prone to aggregation, 
producing particles of hydrodynamic diameters ranging from ~480-1200 nm (Figure 3.3, D-F 
and Table 3.1). These samples showed only slightly negative zeta potential values (-0.6 to -2.5 
mV) which suggests a strong tendency to aggregate as confirmed by the observed size 
distribution data (Table 3.1). In general, the larger the value of the absolute magnitude of the 
zeta potential (regardless of if positive or negative), the more stable the particles in the solution. 
These samples also showed modest polydispersity indices (0.5-0.6) suggesting a large 
distribution of sizes, typical of particles that tend to aggregate (Table 3.1). In comparison, the 
Au-RNA particles showed a primary population of small size hydrodynamic diameters, ~24-30 




potentials of larger absolute values (-12 to -17 mV) and lower polydispersity indices (0.37-0.51) 
when compared to the RNA controls (Table 3.1). These results respectively suggest particles 
with higher stability in solution and narrow size distributions that may render them applicable to 
cell biology applications.  
 
Table 3.1. DLS data for RNA hybrids with and without gold nanoparticles.a 
Samples Effective Particle Size (nm) Polydispersity Index Zeta Potential 
75A1S1 674 ± 146 0.55 ± 0.11 -1.1 ± 0.58 
NSA1S1 1186 ± 77 0.58 ± 0.03 -0.6 ± 0.58 
75A1S1C16 484 ± 50 0.63 ± 0.10 -2.5 ± 1.40 
75A1S1_Gold 24 ± 2 0.37 ± 0.09 -17.6 ± 1.7 
NSA1S1_Gold 19 ± 2 0.51 ± 0.06 -12.6 ± 1.2 
75A1S1C16_Gold 102 ± 66 0.41 ± 0.07 -17.1± 1.65 
aTable reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, 
U.; Zilberberg, J.; Sabatino, D. J Mater Chem B. 2020, 8(10), 2169-217.49 
The TEM images were consistent with the DLS data and provided further insight into 
particle sizes, morphology, and extent of aggregation for the linear RNA hybrid controls 
(75A1S1, NSA1S1, and 75A1S1C16) and the corresponding Au-RNA (75A1S1_Gold, 
NSA1S1_Gold, and 75A1SC16_Gold) particles. Most notably, the Au-RNA samples were found 
to be 10-20-fold smaller when compared to the RNA hybrid controls. For example, the Au-RNA 
(Figure 3.3, A-C) samples formed small, spherical nanoparticles (~15-44 nm) whereas the linear 
RNA hybrid controls (Figure 3.3, D-F) produced larger, non-uniform, polydisperse aggregates 




particles in the control RNA hybrid (Figure 3.3, F) when compared to the Au-RNA particles 
(Figure 3.3, C). It can be rationalized that in the absence of the Au nanoparticles, palmitamide 
provided an increase in RNA amphiphilicity which enhanced sample sizes (~124-1861 nm) and 
the potential for aggregation in aqueous media.46 However, the Au-RNA nanoparticle 
formulation effectively served to restrict size, shape, while maintaining high surface zeta 
potentials which minimizes aggregation, making the nanoparticles applicable to cell uptake and 





Figure 3.3. Representative TEM images (grayscale pictures) and corresponding DLS derived 
size distributions (red histograms) of Au-RNA hybrids (A) 75A1S1_Gold, (B) NSA1S1_Gold 
and (C) 75A1S1C16_Gold, and corresponding RNA hybrid controls (D-F) respectively. Figure 
reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; 






3.4.3. Biological Activity of Au-RNA Nanoparticles 
Following evaluation of chemical and physical properties, the biological activity of the Au-
RNA nanoparticles was evaluated in a metastatic prostate (PC-3) cancer cell line. Initially, cell 
uptake experiments were conducted to establish the cell delivery potential of the Au-RNA 
nanoparticles with and without the commercial Trans-IT X2® dynamic delivery system 
functioning as a suitable RNA transfection reagent in suspension and adherent cancer cell lines.51 
Cell Insight CX5 high content screening microscopy (Thermo Fisher Scientific) was used to 
compare and visualize the time-dependent (2-30 h) cell uptake of the bifunctional FITC-labeled 
Au-RNA nanoparticle formulation in the absence of a transfection reagent (Figure 3.4, A). 
Significantly, an increase in fluorescence (FITC) signaling was observed as a function of time, 
which exceeded the signal detected by the control non-functionalized gold nanoparticles and the 
FITC-labeled RNA transfected with the commercial Trans-IT X2® dynamic delivery system 
(Figure 3.5). Thus, the FITC-labeled Au-RNA nanoparticle formulation was found to be 
amenable to direct PC-3 cell transfection, in the absence of an additional delivery system.  Cell 
uptake was also detected in the absence of the C16 (palmitamide) group, which according to a 
previous study was incapable of achieving efficient RNA cell uptake for biological activity, 
presumably due to the large aggregated structures observed.46 Moreover, it was also 
hypothesized that the enhanced fluorescence emission observed from the direct transfection of 
the FITC-labeled Au-RNA nanoparticles may be attributed to the intracellular separation and 
release of the FITC-labeled S1 strand from the Au-RNA nanoparticle formulation.  
In order to provide supporting evidence into the increase in fluorescence emission signal from 
the bifunctional FITC-labeled Au-RNA nanoparticles, time-dependent FITC absorption and 




°C for 24 h (Figure 3.4, B). Increases in sample absorption (λabs: 495 and 530 nm) and 
fluorescence emission (λem: ~525 nm) as a function of time (2-24 h) were detected under 
physiological conditions (10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA, pH 7.1) which 
served to mimic sample conditions for the cell uptake experiments. The two observable 
absorption bands once again served to support the presence of the bifunctional FITC-labeled Au-
RNA formulation, with characteristic absorption bands for FITC (λabs: 495 nm) and the surface 
plasmon band (λabs: 530 nm) for the metallic (Au) component. Comparatively, the FITC-labeled 
RNA samples absent of the Au component also produced strong increases in fluorophore 
absorption and emission into the visible (green) region. Taken together, the bifunctional FITC-
labeled Au-RNA nanoparticles effectively serve as time-dependent molecular beacons, emitting 
enhanced signal detection with time under physiological conditions that are applicable to cell 
biology. This phenomenon is critically important to enhanced sample detection in cancer cells 
that may lead to early-stage diagnosis and/or preventative treatment regimens.  
The RNAi activity of Au-siRNA nanoparticles (75A1S1_Gold, NSA1S1_Gold, and 
75A1S1C16_Gold) along with the unfunctionalized siRNA controls (75A1S1, NSA1S1, and 
75A1S1C16) targeting GRP75 was next evaluated in the PC-3 cells. The siRNA controls were 
transfected with the Trans-IT X2® dynamic delivery system while the Au-siRNA nanoparticles 
were transfected directly and without the use of any transfection reagent. The knockdown 
efficiency was monitored by western blot at 72 h post-transfection. Downregulation of GRP75 
protein expression levels (Figure 3.4, C) was observed to a comparable extent for the control 
siRNA sample (75A1S1_TX2) as well as the Au-siRNA nanoparticle formulation 
(75A1S1_Gold), validating its utility in downstream biological assays. Moreover, a serum 




h (Figure 3.4, D), whereas the control, naked siRNAs, even with the C16 palmitamide group 
proved to be much more susceptible to nuclease degradation, even after a much shorter 
incubation period (2 h). 
 
Figure 3.4. Biological activity of Au-siRNA nanoparticles. (a) Time-dependent (2-30 h) direct 
PC-3 cell uptake detection of bifunctional FITC-labeled Au-siRNA nanoparticles. Images were 
captured at 10X magnification. (b). Time-dependent (1-24 h) FITC (FL) fluorescence emission 
detection (λmax: 522 nm) of (X1) FITC-labeled siRNA; (X2) FITC-labeled Au-siRNA and Time-
dependent (1-24 h) FITC absorption detection (λmax: 495-500 nm) of (Y1) FITC-labeled siRNA; 
and Au absorption detection (λmax: 530 nm) (Y2) FITC-labeled Au-siRNA at 37 °C, (c). Western 
blot of GRP75 knockdown in PC-3 cells, and (d). Serum stability (10% FBS) of linear, control 
siRNA (75A1S1), C16 palmitamide conjugated siRNA (75A1S1C16), Au-siRNA 




C16 refers to palmitamide conjugation, 75 refers to GRP75 silencing siRNA, A1, S1 refers to the 
antisense, and sense dsRNA strands, NS refers to the non-specific dsRNA control. FITC (FL) or 
C16 (palmitamide) conjugation of the sense (S1) strand. Figure reproduced with the permission 
from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; Samuni, U.; Zilberberg, J.; Sabatino, D. J Mater 





























Figure 3.5. High content screen microscopy images for PC-3 cell uptake by FITC-tagged RNA 
hybrids and citrate-stabilized gold nanoparticles at 30 h with the Trans-IT X2® dynamic delivery 
system. Figure reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, J.A.; 









A cell viability stain using Annexin/PI confirmed the toxicity of the Au-siRNA formulation, 
providing a significant increase (40-50%) in early and late-stage apoptosis relative to the control 
conditions (30-35%), in which siRNA was transfected with the commercial Trans-IT X2 
dynamic delivery system (Figure 3.6). Thus, this novel Au-siRNA formulation may enable a 






Figure 3.6. Flow cytometry data for PC-3 cell viability using Annexin V-PI stain. Detection of 
live cells (Annexin V-, 7AAD-), early (Annexin V+, 7AAD-) and late (Annexin V+, 7AAD+) 
stage apoptosis, and necrosis (Annexin V-, 7AAD+). Quadrants indicate cell viability as the 
following: AK3 (1) healthy cells; AK1 (1) cells undergoing early apoptosis; AK2 (1) cells 
undergoing late apoptosis and AK4 (1) necrotic cells. PC-3 cells treated with i. no treatment, Au 
nanoparticles at 1 µg (ii.) and 2.5 µg (iii.) iv. GRP75 siRNA + Trans-IT X2 dynamic delivery 
system, v. non-specific siRNA control + Trans-IT X2 dynamic delivery, vi. GRP75 C16-siRNA, 
vii.  GRP75 siRNA-Au, viii., non-specific siRNA-Au, and viv. GRP75 C16-siRNA-Au 
nanoparticles. Figure reproduced with the permission from: Shah, S.S.; Cultrara, C.N.; Ramos, 






This thesis chapter describes the synthesis, characterization, and biological evaluation of 
a new class of bifunctional Au-RNA nanoparticles. A newly developed, simple, bottom-up 
approach using alkylamino modified RNAs produced stable and small Au-RNA nanoparticle 
formulations bearing either a fluorescent reporter or a fatty acid group to track cell uptake in PC-
3 PCa cells. Significantly, the bifunctional FL-labelled Au-siRNA nanoparticles absent of a C16 
palmitamide delivery vector or an external commercial transfection reagent enabled direct cell 
uptake in PC-3 cells, which led to concomitant GRP75 knockdown and cell death. Consequently, 
this novel Au-RNA theranostic approach may significantly enable early detection and treatment 
in PCa and related solid tumors. Our on-going and future work are aimed at incorporating cell-
targeting ligands within the Au-siRNA nanoparticle formulation to effect specific cancer 
detection and treatment in cell cultures and within tumor-bearing mice models.  
3.6 Experimental Section 
3.6.1. Materials and Method 
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich, and 
VWR and used as received. Solid-phase RNA synthesis reagents were obtained from 
ChemGenes or Glen Research Inc. and used without further purification. Citrate stabilized Au 
nanoparticles (~20 nm) used as controls were obtained as a gift sample from BBI Solutions, 
Cardiff, UK. Materials for cell biology were obtained from Thermo Fisher Scientific, Cell 
Signaling, Bio-legend, Mirus, and Invitrogen Life Technologies and used as received according 





3.6.2 Solid phase RNA Synthesis 
 
Synthesis of alkyl (C6) amino linker GRP75 antisense RNA (5’-UUG UAU UCU CCG 
AGU CAG U-3’), sense RNA (5’-ACU GAC UCG GAG AAU ACU A-3’), and alkylamino 
linked nonspecific antisense RNA (5’-AGU UCA ACG AGU AUC AGA A-3’) and sense RNA 
(5’- UGC UGA UAC UCG UUG AAC U-3’) were performed on a 2000 Å UnyLinker controlled 
pore glass (CPG) support (ChemGenes) using a 1.0 µmol scale automated synthesis cycle on an 
ABI 3400 DNA synthesizer. All phosphoramidites were dissolved in anhydrous MeCN yielding 
0.15 M solutions. The coupling times were 300 s using 0.25 M 5-ethylthiotetrazole (ETT) in 
MeCN as an activator. The detritylation times were set to 120 s using a solution of 3% 
dichloroacetic acid in CH2Cl2 (DCM). Capping and oxidation steps were performed using a 
mixture of acetic anhydride/N-methyl imidazole in MeCN and a solution of 0.01 M iodine in 
Pyr/THF/H2O respectively. Following synthesis, oligonucleotides were cleaved from the CPG 
and deprotected with NH4OH: EtOH (3:1 v/v) for 12-16 h. at 55 °C. The crude oligonucleotides 
were evaporated to dryness and re-suspended in a mixture of 1:1.5 v/v DMSO: triethylamine 
trihydrofluoride (100 µL:150 µL, 250 µL) to complete the 2’-desilylation reaction at 65 °C for 
120 min. The crude RNA was precipitated from the reaction mixture with 3.0 M NaOAc (25 µL, 
pH = 5.2) in n-BuOH (500 µL). Precipitation was completed in -80 °C freezer 30 min prior to 
centrifugation (12,000 rpm, 5 min) leaving the crude oligonucleotides as a solid white pellet. 
Crude oligonucleotides were evaporated to dryness and resuspended in autoclaved water (1.0 
mL) and the yields were determined by UV absorbance measurements at 260 nm. Crude RNA 
was purified by reverse-phase-ion pair HPLC on a Waters 2695 Alliance system equipped with a 
symmetry RP-C18 reverse-phase column (4.6 x 250 mm, 5 µm particle size) and gradient elution 




eluent A (0.1 M TEAA). The HPLC flow rate was set at 1.0 mL/min, with run times of 27 min 
and with absorbance detection at 260 nm using a Waters 2489 UV/visible detector. Retention 
times (min) and peak areas (% area) were integrated with Empower II software (Waters) and 
used to confirm RNA purities. RNA-bioconjugation was conducted as described previously45,46 
for the generation of palmitamide and FITC-conjugated GRP75 RNA. 
3.6.3. Synthesis of Au-siRNA particles 
Equimolar concentrations (1.25 µM) of alkyl amino-linked antisense RNA and 
complementary sense RNA functionalized with or without palmitamide or FITC were combined 
in annealing buffer (10 mM Tris, pH 7.5-8.0, 50 mM NaCl, 1 mM EDTA, pH 7.5-8) in a 1.5 mL 
screw-cap Eppendorf tube in the absence and presence of hydrogen tetrachloroaurate (III) 
trihydrate (HAuCl4.3H2O, 0.01 M). The sample was vortexed briefly and trisodium citrate was 
then added as a mild reducing agent to the mixture which was incubated on a standard heat block 
at 95 ± 1 °C for 5 min. The samples were then allowed to slowly cool to room temperature (22 
°C) before cooling at 4 °C for 24 h prior to sample analysis. In-situ nucleation and growth of Au 
nanoparticles were clearly observed by the formation of a red color solution due to the unique 
optical properties of Au nanoparticles.  
3.6.4. UV-Vis Spectroscopy 
Optical absorption spectra were acquired with a CARY 3E UV-Vis spectrophotometer. 
Absorption measurements were recorded between 210-310 nm for RNA samples, which were 




RNA nanoparticles were acquired between 220-750 nm with a CARY 3E/nanodrop UV-Vis 
spectrophotometer.  
3.6.5. Reverse Phase Ion Pairing High-Performance Liquid Chromatography (RP IP HPLC) 
The crude RNA samples were analyzed by Reverse Phase Ion Pairing High-Performance 
Liquid Chromatography (RP IP HPLC) to determine crude purities. Briefly, HPLC analyses 
(~0.1 OD) and purifications (1 OD) were performed on a Waters 2695 Alliance Separations 
Module. Crude RNA templates were dissolved in autoclaved water (1.0 mL) and injected into a 
Waters symmetry RP C18 reverse-phase column (4.6 x 250 mm, 5.0 µm particle size) heated at 
60 °C. HPLC analyses and purifications for RNA controls were conducted using a gradient of 
20−90% eluent B (20 % acetonitrile in 0.1 M triethylammonium acetate, TEAA) in eluent A (0.1 
M TEAA) with a flow rate of 1 mL/min, run time of 30 min and with absorbance detection at 
260 nm using a Waters 2489 UV/Visible detector. Similarly, RP IP HPLC for fatty acid 
conjugated RNAs were conducted using a gradient of 7-70% eluent C (100% acetonitrile) in 
eluent A (0.1 M triethylammonium acetate), with a run time 40 min and sample detection at 260 
nm. Retention times (min) and peak areas (% area) were integrated with Empower II software 
and used to confirm RNA purities >90% following sample purifications. 
3.6.6. Dynamic Light Scattering (DLS)  
A Malvern Zetasizer, Nano-ZS (Malvern Instruments, UK) employing a 173° scattering 
angle and a 4-mW incident He-Ne laser (633 nm) was used to measure the particle sizes 
(hydrodynamic diameter), size distributions, and zeta potentials of the control siRNA hybrids 




samples were loaded into folded capillary cells (DTS 1070) equipped with electrodes on both 
sides to allow measurement of their zeta potentials and by extension, the stability and degree of 
aggregation. Particle suspensions with highly positive or highly negative zeta potentials are 
considered stable because the electrical repulsion between the particles tends to counter the van 
der Waals forces that would otherwise result in aggregation and precipitation. 
3.6.7. Transmission Electron Microscopy (TEM) 
TEM analyses of the linear control siRNA hybrids along with the Au-siRNA 
nanoparticles were performed with a JEOL 1200EX Transmission Electron Microscope (JEOL 
Ltd, Japan) at an accelerating voltage of 80 kV. A mixture of 1:1 volume ratio 1.0 % uranyl 
acetate and sample suspension were prepared and 10 µL of this solution was placed on a TEM 
carbon-film-coated copper grid of 300 mesh (Electron Microscopy Sciences Inc., Hatfield, PA). 
Each sample was allowed to sit for five minutes on the grid before wicking the excess liquid 
followed by storage for 12-24 h to allow the samples to dry. Images were taken with an SIA-L3C 
CCD camera (Scientific Instruments and Applications, Inc.) using the software Maxim DL5 
(Diffraction Limited, Ottawa, Canada). 
3.6.8. Serum Stability Assay 
siRNA samples were hybridized and formulated as previously described in annealing 
buffer (30 µM, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.1, 50 µL). An aliquot (50 µL, 30 
µM) was added to a 10% FBS solution (50 µL in phosphate buffer, pH 7.4). The mixtures were 
incubated at 37 °C and periodically (0-24 h) sample aliquots (15 µL) were removed and frozen at 




% sucrose loading buffer and analyzed on a 24% denaturing PAGE for 2.5 h. The gel was then 
visualized with a Stains-All (Sigma-Aldrich™) solution.  
3.6.9. Time-Dependent Absorption and Emission Assays 
FITC-labeled siRNA samples with and without gold nanoparticles were hybridized and 
formulated as previously described in annealing buffer (5 µM, 10 mM Tris, 50 mM NaCl, 1 mM 
EDTA, pH 7.5–8.0, 75 µL) and allowed to slowly cool to room temperature (22 °C) before 
cooling at 4 °C for 24 h prior to sample analysis. The Spark multimode microplate reader 
equipped with Spark ControlTM Excel software was used to study the time-dependent absorption 
and emission spectra at 37 °C. The FITC-labeled siRNA controls and FITC-labeled Au-siRNA 
samples (75 µL, 5 µM) were placed in low volume microplate reader incubated at 37 °C. Time-
dependent absorption (350-800 nm) and emission (490-700 nm) scans were programmed and 
collected for 24 h. analyses.  
3.6.10. Cell Culture  
Prostate cancer cell line PC-3 (ATCC® CRL-1435™) was purchased from ATCC and 
cultured in RPMI-1640 complete growth medium supplemented with 10% (v/v) fetal bovine 
serum (FBS), 2.5 mM of L-glutamine, and 1% (v/v) penicillin/streptomycin (P/S) under 5% CO2 







3.6.11. siRNA transfections, cell uptake, and viability in PC-3 cells 
PC-3 cells were grown in 24-well culture plates in RPM-1640 complete growth media 
until 60-70 % confluence as per the 3.6.10 protocol. Prior to transfections, the nonspecific and 
control siRNA hybrids (2.5 µL, 10 µM, in Opti-MEM, 137.5 µL) were mixed with the 
transfection reagent (TransIT-X2® Dynamic Delivery System, 9 µL, in Opti-MEM, 250 µL) and 
kept at 37 °C for 15 minutes according to the manufacturer’s recommendation. Both the linear 
siRNAs and nonspecific siRNA hybrids complexed with the commercial Tran-IT X2 transfection 
reagent in Opti-MEM was added to the cells at final concertation of 25 nM. RNA bioconjugates 
templated to Au such as the palmitamide or FITC-siRNA-Au samples were transfected directly, 
in the absence of an external transfection reagent, at a final concentration of 25 nM. The 
mixtures were incubated (15 min, 22 °C) then added to the PC-3 cell culture and incubated at 37 
°C with 5% CO2 over a three-day (72 h) period. To determine time-dependent cell uptake, FITC-
labeled siRNA samples with and without Au nanoparticles were transfected with and without the 
commercial transfection reagent along with their respective controls. Cell-uptake was determined 
using a Cell Insight CX5 High Content Screening (HCS) Platform (Thermo Fisher Scientific). 
Cells were visualized for 2, 4, and 30 h post-transfection. Images were analyzed using Thermo 
Scientific HCS Studio Cell Analysis software. Similarly, cell viability was performed in a 24-
well plate with PC-3 cells cultured in RPMI-1640 complete growth media and incubated with 
samples for 24 h at 37 °C. Briefly, after 24 h the supernatant was collected, and the remaining 
cells were removed using trypsin. Cell samples were pelleted and resuspended in 1% bovine 
serum albumin in phosphate-buffered saline (1 mL) and stained using Annexin-PI according to 
the manufacturer’s recommendation. Data was collected on an FC 500 flow cytometer (Beckman 




3.6.12. Western Blot 
Total protein was isolated from the cell cultures following transfection (72 h). Protein 
lysates were prepared by lysing the cells in ice-cold RIPA buffer (G-Biosciences) supplemented 
with protease and phosphatase inhibitors (Millipore Sigma) which were diluted 1:10 v/v as per 
the manufacturer’s recommendations. Cell debris was removed by centrifugation at 16,000g at 4 
°C and protein concentrations were determined using a Pierce™ BCA kit (Thermo Fisher 
Scientific). A sample (20-35 mg) of the supernatant protein was mixed with LDS buffer and 
DTT, incubated at 70 °C for 10 min, and resolved on a 4-12% Bis-Tris PAGE gradient gel before 
being transferred to a PVDF membrane. Following the transfer, the membrane was blocked in 
5% skim milk for 1 h, washed and incubated at 4 °C overnight with a rabbit 1° monoclonal 
antibody against human GRP75 and -Actin (all purchased from Cell Signaling Technology) at a 
1:1000 dilution. The membrane was subsequently washed and incubated with an anti-rabbit 
HRP-conjugated 2° Ab (Cell Signaling Technology) for 1 h at room temperature at 1:2000 
dilution. The bands were visualized using a Signal Fire™ ECL reagent (Cell signaling 
Technology) on a Protein Simple Fluor Chem E imager. 
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Chapter 4: Conclusions, Contributions to Knowledge, and Future Work 
4.1 Conclusions and Contributions to Knowledge Made in this Thesis 
4.1.1 Investigating the role of siRNA bioconjugates and their nanoparticle formulations for 
improved biological activity   
 siRNA-based therapeutics have been developed over the course of the last two decades in 
precision medicine applications of difficult-to-treat diseases, including those that are genetically 
driven. The advancement of novel synthetic techniques has provided a diverse class of modified 
siRNAs with improved pharmacological properties resulting in more potent RNAi applications. 
However, their limited cell uptake has restricted their widespread therapeutic utility. To address 
these limitations, gene delivery systems have been engineered and optimized for siRNA delivery 
in vitro and in vivo. Among the more appealing are the non-viral based delivery methods that 
implicate bioconjugation strategies for the ligation of cell targeting/delivery vectors, 
polycationic/amphiphilic synthetic and biological polymers as well as biocompatible inorganic 
materials which enable siRNA functionalization or encapsulation for delivery applications.  
In our contributions for improving the structure-function properties of siRNAs, the design 
and development of higher-ordered RNA templates that can self-assemble into multifunctional 
siRNA nanostructures have served to expand the scope of bioactive siRNA candidates while 
enhancing their therapeutic potential in cancer gene therapy applications. This is because the 
self-assembled siRNA nanostructures may be used to effectively screen and silence multiple 
oncogenes leading to a synergistic knockdown and therapeutic effects. In this manner, the 
higher-order siRNA nanostructures served as important tools in the knockdown of oncogenic 
Glucose Regulated Proteins (GRPs), in various cancerous cells leading to potent anti-cancer 




around improving the utility of synthetic siRNAs in cancer gene therapy by either bioconjugation 
and/or formulation into multifunctional nanoparticles applicable for direct transfection and RNAi 
activity. In this manner, the novel siRNA constructs disclosed in this thesis are based on higher-
order siRNA bioconjugates bearing either fatty acids or fluorescein labels used for tracking cell 
uptake efficacy for RNAi activity in prostate cancer cells. Our contributions towards the 
development of a novel platform for functionalizing siRNAs onto Au surfaces were used for the 
generation of multifunctional Au-siRNA nanoparticles for theranostic (therapy+diagnostic) 
activity in prostate cancer cells. These contributions led to target-specific silencing of the GRPs, 
which impacted key roles in the development, progression, and spread of cancer. Thus, novel 
methods for the generation of higher-order siRNA motifs and their bioconjugation with 
functional probes may serve to improve cellular uptake for more potent RNAi activity in cancer 
gene therapy applications (Figure 4.1). 
 
 
Figure 4.1. Next-generation siRNA motifs for cancer gene therapy applications. Figure Drawn 
using Chemdraw version 19.1 software. 
 





 Chapter 2 discussed our specific efforts on the development of an effective technique for 
the cellular delivery of our higher-order siRNA structures, including those adopting V-, and Y- 
shape siRNA for knockdown of GPRs, upregulated in various cancers. More specifically, in this 
chapter, a bioconjugation approach was developed for the incorporation of a series of saturated 
and unsaturated fatty acids within linear, V- and Y-shape siRNAs to improve cellular uptake and 
knockdown efficacy of the oncogenic GRPs in a model prostate cancer (PC-3) cell line (Figure 
4.2). These fatty-acid conjugated siRNA motifs provided valuable insights into the requisite 
amphiphilicity for cell uptake activity. The solid-phase RNA bio-conjugation approach reported 
in this study provided an important entry point for the incorporation of various hydrophobic and 
amphiphilic functional groups onto higher-order, multifunctional siRNA constructs, A small set 
of linear saturated and unsaturated fatty acids (C12 to C18 carbon chain lengths) was 
successfully conjugated to the RNA templates with both antisense and sense sequences. The 
amphiphilic siRNA-fatty acid motifs incorporating a fluorescent (FITC) label for tracking cell 
uptake indicated initial (6 h) transfection with little observed cellular siRNA left following 24 h 
incubation. The modest cell uptake effects translated into a moderate GRP knockdown (~30-
40%) within PC-3 cells, albeit without the use of a commercial transfection reagent (Figure 2.7). 
To better understand the observed moderate cell uptake and GRP knockdown effects of the fatty 
acid labeled siRNAs, structural characterization by DLS and TEM revealed very large, 
aggregated particles (Figure 2.6 and Table 2.3), which in-turn likely contributed to the 
moderate RNAi effects in the PC-3 cell line. Taken together, these results confirm the ability to 
modulate siRNA structure-function properties via conjugation of bio-active probes (e.g. fatty 
acids and fluorophores). However, effective siRNA activity is dependent on a variety of factors 




method for generating suitable formulations capable of effective siRNA delivery and release for 
silencing of important oncogene targets in cancer gene therapy applications. 
 
Figure 4.2. Fatty acid conjugated siRNAs with a fluorescence probe (fluorescein) for tracking 




4.1.3 Development of Bifunctional Au-templated RNA nanoparticle formulation for siRNA activity in 
PCa Cells 
 A major limitation of the self-assembled siRNA structures and the bioconjugates 
described in chapter 2, was based on their limited cell uptake for silencing activity in PC-3 cells. 
Structural studies by DLS and TEM revealed that large, charged aggregates likely contributed to 
poor cell uptake which diminished RNAi activity. Thus, modification strategies for fine-tuning 
the structure-function properties of siRNAs must optimize the requisite size and surface charge 
density of particles that may be applicable to cell uptake for RNAi potency. Chapter 3 of this 
thesis focused on the design and development of bifunctional RNA nanoparticles based on a Au 




cell-uptake and RNAi activity in PC-3 cells. In this application (Figure 4.3), a simple method for 
templating amino-functionalized RNA onto Au surfaces and their self-assembly into small, 
discrete siRNA nanoparticles was established and also extended to our bioconjugation 
approaches for the incorporation of palmitamide and fluorescein. In this newly developed 
synthetic method (Scheme 3.1), a novel bottom-up approach for nucleating synthetic double-
stranded (ds) RNA in which the antisense (A1) strand bearing a reactive alkylamino linker was 
used to template RNA onto the surface of reduced Au particles. The complementary sense (S1) 
strand was functionalized with and without a palmitamide (C16) fatty acid group or fluorescein 
isothiocyanate (FITC) as fluorescent (FL) reporter to generate the bifunctional Au-templated 
siRNA particles. It was observed that the Au-functionalized RNA particles with and without the 
fatty acid or fluorophore appendages were found to be stable under reducing conditions 
according to UV-Vis spectroscopy (Figure 3.4). These samples also produced primarily small 
(~10-40 nm), well-defined spherical shaped self-assembled nanoparticles (Figure 3.5), which 
were expected to be amenable to cell biology. The introduction of FITC within the Au-
functionalized RNA particles produced a bifunctional probe, in which FITC fluorescence 
emission (λexc: 494 nm, λem: 522 nm) facilitated cell uptake detection, in a time-dependent 
manner (Figure 3.6, A and B). Moreover, western blot data showed knockdown of GRP75, 
which led to detectable levels of cell death in PC-3 cells treated with the Au-siRNA formulation 
in the absence of a transfection vector. Thus, the methodology shows the formulation of stable, 
small, and discrete Au-functionalized RNA nanoparticles, which may prove to be valuable 





Figure 4.3. Structural representation of the multifunctional Au-siRNA nanoparticles bearing 
either a palmitamide or fluorescein group for cell biology in PC-3 prostate cancer cells. Figure 
drawn using Chemdraw version 19.1 software. 
 
4.2. Ongoing and Future Work 
 While the results in this thesis highlight important accomplishments in the design and 
development of higher-order siRNA bioconjugates and their nanoparticle formulations for 
enhancing cell uptake and silencing of GRP expression for anti-cancer activity in prostate cancer 
cells, there is still the need for further refinement and optimization. Among the areas that remain 
underexplored and underdeveloped in our research work, are the cell-targeting ligands, that 
provide specificity and targetability, for minimizing off-target gene silencing effects while 
improving the efficacy of our cancer-targeted gene therapy approach. The ongoing and future 
work is aimed at the incorporation of polyarginine derived cell-targeting peptides that own the 
ability to bind and release siRNAs selectively within targeted cell lines. Our previous work 




uptake efficacy due to the large, aggregated particles observed. In order to address this 
limitation, we are working on developing Au-siRNA formulations that contain cell-targeting 
peptides that own the ability to bind selectively onto the PSMA receptor localized on the surface 
of prostate cancer cells (Figure 4.4). In this manner, we anticipate that the Au-RNA formulation 
functionalized with the PSMA specific peptide may further improve the targetability, stability, 
and potency of the formulation for the requisite RNAi response in prostate cancer cells that may 
ultimately lead to the desired cancer-targeted gene therapy applications.  
 
Figure 4.4. Proposed PSMA-targeting Au-siRNA formulation for targeted gene therapy in 
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Figure A2  HPLC chromatogram of amino-functionalized GRP75 S1 RNA 
 








Figure A3  HPLC chromatogram of amino-functionalized NS A1 RNA 
 













Figure A5 HPLC chromatogram of C16 conjugated GRP75 S1 RNA 
 
 
 
 
